Podcasts about BMS

As 2026 gets underway, healthcare and life sciences face a year of both promise and pressure, with investment, innovation and equity all in sharp focus. In Part 1 of this year's pharma forecast, four leaders explore where real opportunity lies, from health investment to personalisation and women's health, alongside the key threats that could slow progress.  Speaker bios Dheepa Chari Vice President and Head of Global Scientific Communications, GSK Dheepa leads strategy and execution across oncology, vaccines, specialty care and general medicine, driving innovation in how scientific narratives are delivered. Emma Charles Senior Vice President of European Markets, BMS Emma oversees BMS operations across 19 countries, bringing extensive global leadership experience spanning Europe, Asia, Latin America and the Middle East. Mary Stutts CEO, Healthcare Businesswomen's Association Mary leads a global organisation advancing the impact of women in healthcare, and is a prominent advocate for inclusive leadership, representative workforces and health equity.

Dr. Pedro Barata and Dr. Ugwuji Maduekwe discuss the evolving treatment landscape in gastroesophageal junction and gastric cancers, including the emergence of organ preservation as a selective therapeutic goal, as well as strategies to mitigate disparities in care. Dr. Maduekwe is the senior author of the article, "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Primetime?" in the 2026 ASCO Educational Book. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also the deputy editor of the ASCO Educational Book. Gastric and gastroesophageal cancers are the fifth most common cancer worldwide and the fourth leading cause of cancer-related mortality. Over the last decade, the treatment landscape has evolved tremendously, and today, organ preservation is emerging as an attainable but still selective therapeutic goal. Today, I'm delighted to be speaking with Dr. Ugwuji Maduekwe, an associate professor of surgery and the director of regional therapies in the Division of Surgical Oncology at the Medical College of Wisconsin. Dr. Maduekwe is also the last author of a fantastic paper in the 2026 ASCO Educational Book titled "Organ Preservation for Gastroesophageal Junction and Gastric Cancers: Ready for Prime Time?" We explore these questions in our conversations today.  Our full disclosures are available in the transcript of this episode as well. Welcome. Thank you for joining us today. Dr. Ugwuji Maduekwe: Thank you, Dr. Barata. I'm really, really glad to be here. Dr. Pedro Barata: There's been a lot of progress in the treatment of gastric and gastroesophageal cancers. But before we actually dive into some of the key take-home points from your paper, can you just walk us through how systemic therapy has emerged and actually allowed you to start thinking about a curative framework and really informing surgery decision-making? Dr. Ugwuji Maduekwe: Great, thank you. I'm really excited to be here and I love this topic because, I'm terrified to think of how long ago it was, but I remember in medical school, one of my formative experiences and why I got so interested in oncology was when the very first trials about imatinib were coming through, right? Looking at the effect, I remember so vividly having a lecture as a first-year or second-year medical student, and the professor saying, "This data about this particular kind of cancer is no longer accurate. They don't need bone marrow transplants anymore, they can just take a pill." And that just sounded insane. And we don't have that yet for GI malignancies. But part of what is the promise of precision oncology has always been to me that framework. That framework we have for people with CML who don't have a bone marrow transplant, they take a pill. For people with GIST. And so when we talk about gastric cancers and gastroesophageal cancers, I think the short answer is that systemic therapy has forced surgeons to rethink what "necessary" really means, right? We have the old age saying, "a chance to cut is a chance to cure." And when I started out, the conversation was simple. We diagnose the cancer, we take it out. Surgery's the default. But what's changed really over the last decade and really over the last five years is that systemic therapy has gotten good enough to do what is probably real curative work before we ever enter the operating room. So now when you see a patient whose tumor has essentially melted away on restaging, the question has to shift, right? It's no longer just, "Can I take this out?" It's "Has the biology already done the heavy lifting? Have we already given them systemic therapy, and can we prove it safely so that maybe we don't have to do what is a relatively morbid procedure?" And that shift is what has opened the door to organ preservation. Surgery doesn't disappear, but it becomes more discretionary. Necessary for the patients who need it, and within systems that can allow us to make sure that we're giving it to the right patients. Dr. Pedro Barata: Right, no, that makes total sense. And going back to the outcomes that you get with these systemic therapies, I mean, big efforts to find effective regimens or cocktails of therapies that allow us to go to what we call "complete response," right? Pathologic complete response, or clinical complete response, or even molecular complete response. We're having these conversations across different tumors, hematologic malignancies as well as solid tumors, right? I certainly have those conversations in the GU arena as well. So, when we think of pathologic CRs for GI malignancies, right? If I were to summarize the data, and please correct me if I'm wrong, because I'm not an expert in this area, the traditional perioperative chemo gives you pCRs, pathologic complete response, in the single digits. But then when you start getting smarter at identifying biologically distinct tumors such as microsatellite instability, for instance, now you start talking about pCRs over 50%. In other words, half of the patients' cancer goes away, it melts down by offering, in this case, immunotherapy as a backbone of that neoadjuvant. But first of all, this shift, right, from going from these traditional, "not smart" chemotherapy approaches to kind of biologically-driven approaches, and how important is pCR in the context of "Do I really need surgery afterwards?" Dr. Ugwuji Maduekwe: That's really the crux of the entire conversation, right? We can't proceed and we wouldn't be able to have the conversation about whether organ preservation is even plausible if we hadn't been seeing these rates of pathologic complete response. If there's no viable tumor left at resection, did surgery add something? Are we sure? The challenge before this was how frequently that happened. And then the next one is, as you've already raised, "Can we figure that out without operating?" In the traditional perioperative chemo era, pathologic complete response was relatively rare, like maybe one in twenty patients. When we go to more modern regimens like FLOT, it got closer to one in six. When you add immunotherapy in recent trials like MATTERHORN, it's nearly triple that rate. And it's worth noting here, I'm a health services-health disparities researcher, so we'll just pause here and note that those all sound great, but these landmark trials have significant representation gaps that limit and should inform how confidently we generalize these findings. But back to what you just said, right, the real inflection point is MSI-high disease where, with neoadjuvant dual-checkpoint blockade, trials like NEONIPIGAS and INFINITY show pCR rates that are approaching 50% to 60%. That's not incremental progress, that's a whole new different biological reality. What does that mean? If we're saying that 50% to 60% of the people we take to the OR at the time of surgery will end up having no viable tumor, man, did we need to do a really big surgery? But the problem right now is the gold standard, I think we would mostly agree, the gold standard is pathologic complete response, and we only know that after surgery. I currently tell my patients, right, because I don't want them to be like, "Wait, we did this whole thing." I'm like, "We're going to do this surgery, and my hope is that we're going to do the surgery and there will be no cancer left in your stomach after we take out your stomach." And they're like, "But we took out my stomach and you're saying it's a good thing that there's no cancer." And yes, right now that is true because it's a measure of the efficacy of their systemic therapy. It's a measure of the biology of the disease. But should we be acting on this non-operatively? To do that, we have to find a surrogate. And the surrogate that we have to figure out is complete clinical response. And that's where we have issues with the stomach. In esophageal cancer, the preSANO protocol, which we'll talk about a little bit, validated a structured clinical response evaluation. People got really high-quality endoscopies with bite-on biopsies. They got endoscopic ultrasounds. They got fine-needle aspirations and PET-CT, and adding all of those things together, the miss rate for substantial residual disease was about 10% to 15%. That's a number we can work with. In the stomach, it's a lot more difficult anatomically just given the shape of people's stomachs. There's fibrosis, there's ulceration. A fair number of stomach and GEJ cancers have diffuse histology which makes it difficult to localize and they also have submucosal spread. Those all conceal residual disease. I had a recent case where I scoped the patient during the case, and this person had had a 4 cm ulcer prior to surgery, and I scoped and there was nothing visible. And I was elated. And on the final pathology they had a 7 cm tumor still in place. It was just all submucosal. That's the problem. I'm not a gastroenterologist, but I would have said this was a great clinical response, but because it's gastric, there was a fair amount of submucosal disease that was still there. And our imaging loses accuracy after treatment. So the gap between what looks clean clinically and what's actually there pathologically remains very wide. So I think that's why we're trying to figure it out and make it cleaner. And outside of biomarker-selected settings like MSI-high disease, in general, I'm going to skip to the end and our upshot for the paper, which is that organ preservation, I would say for gastric cancer particularly, should remain investigational. I think we're at the point where the biology is increasingly favorable, but our means of measurement is not there yet. Dr. Pedro Barata: Gotcha. So, this is a perfect segue because you did mention the SANO, just to spell it out, "Surgery As Needed for Oesophageal" trial, so SANO, perfect, I love the abbreviation. It's really catchy. It's fantastic, it's actually a well-put-together perspective effort or program applying to patients. And can you tell us how was that put together and how does that work out for patients? Dr. Ugwuji Maduekwe: Yeah, I think for those of us in the GI space, we have SANO and then we also have the OPRA for rectum. SANO for the upper GI is what takes organ preservation from theory to something that's clinically credible. The trial asked a very simple question. If a patient with a GEJ adenocarcinoma or esophageal adenocarcinoma achieved what was felt to be a clinical complete response after chemoradiation, would they actually benefit from immediate surgery? And the question was, "Can you safely observe?" And the answer was 'yes'. You could safely observe, but only if you do it right. And what does that mean? At two years, survival with active surveillance was not inferior to those who received an immediate esophagectomy. And those patients had a better early quality of life. Makes sense, right? Your quality of life with an esophagectomy versus not is going to be different. That matters a lot when you consider what the long-term metabolic and functional consequences of an esophagectomy are. The weight loss, nutritional deficiencies that can persist for years. But SANO worked because it was very, very disciplined and not permissive. You mentioned rigor. They were very elegant in their approach and there was a fair amount of rigor. So there were two main principles. The first was that surveillance was front-loaded and intentional. So they had endoscopies with biopsies and imaging every three to four months in the first year and then they progressively spaced it out with explicit criteria for what constituted failure. And then salvage surgery was pre-planned. So, the return-to-surgery pathway was already rehearsed ahead of time. If disease reappeared, take the patient to the OR within weeks. Not sit, figure out what that means, think about it a little bit and debate next steps. They were very clear about what the plan was going to be. So they've given us this blueprint for, like, watching people safely. I think what's remarkable is that if you don't do that, if you don't have that infrastructure, then organ preservation isn't really careful. It's really hopeful. And that's what I really liked about the SANO trial, aside from, I agree, the name is pretty cool. Dr. Pedro Barata: Yeah, no, that's a fantastic point. And that description is spot on. I am thinking as we go through this, where can this be adopted, right? Because, not surprisingly, patients are telling you they're doing a lot better, right, when you don't get the esophagus out or the stomach out. I mean, that makes total sense. So the question is, you know, how do you see those issues related to the logistics, right? Getting the multi-disciplinary team, getting the different assessments of CR. I guess PETs, a lot of people are getting access to imaging these days. How close do you think this is, this kind of program, to be implemented? And maybe I would assume it might need to be validated in different settings, right, including the community. How close or how far do you think you see that being applied out there versus continuing to be a niche program, watch and wait program, in dedicated academic centers? Dr. Ugwuji Maduekwe: I love this question. So I said at the top of this, I'm a health equity/health disparities researcher, and this is where I worry the most. I love the science of this. I'm really excited about the science. I'm very optimistic. I don't think this is a question of "if," I think it's a question of "when." We are going to get to a point where these conversations will be very, very reasonable and will be options. One of the things I worry about is: who is it going to be an option for? Organ preservation is not just a treatment choice, and I think what you're pointing out very rightly is it's a systems-level intervention. Look at what we just said for SANO. Someone needs to be able to do advanced endoscopy, get the patients back. We have to have the time and space to come back every three to four months. We have to do molecular testing. There needs to be multi-disciplinary review. There needs to be intensive surveillance, and you need to have rapid access to salvage surgery. Where is that infrastructure? In this country, it's mostly in academic centers. I think about the panel we had at ASCO GI, which was fantastic. And as we were having the conversation, you know, we set it up as a debate. So folks were debating either pro-surveillance or pro-surgery. But both groups, both people, were presenting outcomes based on their centers. And it was folks who were fantastic. Dr. Molena, for example, from Memorial Sloan Kettering was talking about their outcomes in esophagectomies [during our session at GI26], but they do hundreds of these cases there per year. What's the reality in this country? 70% to 80% to 90%, depending on which data you look at, of the gastrectomies in the United States occur at low-volume hospitals. Most of the patients at those hospitals are disproportionately uninsured or on government insurance, have lower income and from racial and ethnic minority groups. So if we diffuse organ preservations without the system to support it, we're going to create a two-tiered system of care where whether you have the ability to preserve your organs, to preserve bodily integrity, depends on where you live and where you're treated. The other piece of this is the biomarker testing gap. One of the things that, as you pointed out at the beginning, that's really exciting is for MSI-high tumors. Those are the patients that are most likely to benefit from immunotherapy-based organ preservation. But here's the problem. If the patient isn't tested at time of initial diagnosis before they ever see me as a surgeon, the door to organ preservation is closed before it's ever open. And testing access remains very inconsistent across academic networks. And then there's the financial toxicity piece where, for gastrectomy, pancreatectomy, I do peritoneal malignancies, more than half of those patients experience significant financial toxicity related to their cancer treatment. We're now proposing adding at least two years, that's the preliminary information, right? It's probably going to be longer. At least a couple of years of surveillance visits, repeated endoscopies, immunotherapy costs. How are we going to support patients through that? We're going to have to think about setting up navigation support, geographic solutions, what financial counseling looks like. My patient for clinic yesterday was driving to see me, and they were talking about how they were sliding because it was snowing. And they were sliding for the entire three-hour drive down here. Are we going to tell people like that that they need to drive down to, right, I work at a high-volume center, they're going to need to come here every three months, come rain or snow, to get scoped as opposed to the one-time having a surgery and not needing to have the scopes as frequently? My concern, like I said, I'm an optimist, I think it is going to work. I think we're going to figure out how to make it work. I'm worried about whether when we deploy it, we widen the already existing disparities. Dr. Pedro Barata: Gotcha, and that's a fantastic summary. And as I'm thinking also of what we've been talking in other solid tumors, which one of the following do you think is going to evolve first? So we are starting to use more MRD-based assays, which are based on blood test, whether it's a tumor-informed ctDNA or non-informed. We are also trying to get around or trying to get more information response to systemic therapies out of RNA-seq through gene expression signatures, or development of novel therapeutics which also can help you there. Which one of these areas you think you're going to help this SANO-like approach move forward, or you actually think it's actually all of the above, which makes it even more complicated perhaps? Dr. Ugwuji Maduekwe: I think it's going to be all of the above for a couple of reasons. I would say if I had to pick just one right now, I think ctDNA is probably the most promising and potentially the missing piece that can help us close the gap between clinical and pathologic response. If you achieve clinical complete response and your ctDNA is negative, so you have clinical and molecular evidence of clearance, maybe that's a low-risk patient for surveillance. If you have clinical complete response but your ctDNA remains positive, I would say you have occult molecular disease and we probably need intensified therapy, closer monitoring, not observation. I think the INFINITY trial is already incorporating ctDNA into its algorithm, so we'll know. I don't think we're at the point where it alone can drive surgical decisions. I think it's going to be a good complement to clinical response evaluation, not a replacement. The issue of where I think it's probably going to be multi-dimensional is the evidence base: who are we testing? Like, what is the diversity, what is the ancestral diversity of these databases that we're using for all of these tests? How do we know that ctDNA levels and RNA-seq expression arrays are the same across different ancestral groups, across different disease types? So I think it's probably going to be an amalgam and we're going to have to figure out some sort of algorithm to help us define it based on the patient characteristics. Like, I think it's probably different, some of this stuff is going to be a little bit different depending on where in the stomach the cancer is. And it's going to be a little bit more difficult to figure out if you have a complete clinical response in the antrum and closer to the pylorus, for example. That might be a little bit more difficult. So maybe the threshold for defining what a clinical complete response needs to be is higher because the therapeutic approach there is not quite as onerous as for something at the GE-junction. Dr. Pedro Barata: Wonderful. And I'm sure AI, whether it's digitization of the pathology from the biopsies and putting all this together, probably might play a role as well in the future.  Dr. Maduekwe, it's been fantastic. Thank you so much for sharing your insights with us and also congrats again for the really well-done review published.  For our listeners, thank you for staying with us. Thank you for your time. We will post a link to this fantastic article we discussed today in the transcript of this episode. And of course, please join us again next month on the By the Book Podcast for more insights on key advances and innovations that are shaping modern oncology. Thank you, everyone. Dr. Ugwuji Maduekwe: Thank you. Thank you for having me. Watch the ASCO GI26 session: Organ Preservation for Gastroesophageal and Gastric Cancers: Ready for Primetime? Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ugwuji Maduekwe @umaduekwemd Follow ASCO on social media:          @ASCO on X (formerly Twitter)          ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ugwuji Maduekwe: Leadership: Medica Health Research Funding: Cigna    

Chapter 129This week Queen tells us about her going to a party with her Dom and we see videos of their BDSM session during the party. Then we discuss all that is going on wit porn and these platforms. Now it's time to podcast and we start with us reacting to two videos from Conversations Tonight. The first one was a lady who had two brain surgeries and she is complaining about her husband not being romantic after he nursed her back to good health. The 2nd one was a lady asking about getting out of and over a lesbian relationship. We unpack both and we discuss the three types of cheater for both men and women. Then , we discuss a lady who has both of her BMs names tatted on her but the real tea is her "I'm His Cum Bucket " Tattoo. Then we unpack bad roommates and more.Watch the Full Episode as a Premium Smoker in The Premium Smoke Room On Loyalfanshttps://tinylf.com/qEOiWRZkp4GCyU9

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the industry landscape, from regulatory advancements to scientific breakthroughs and strategic business maneuvers.Kicking off with a significant regulatory update, the FDA's Rare Pediatric Disease Voucher Program has been rejuvenated through a newly signed government funding bill. This initiative is designed to expedite the development of treatments for rare pediatric diseases, offering crucial incentives to companies targeting this critical healthcare segment. By reauthorizing this program, there's an expectation of stimulating innovation and potentially bringing more treatments to market for conditions with limited existing therapies. This move underscores a broader commitment to addressing unmet medical needs through incentivized innovation.Turning to corporate developments, Eli Lilly is anticipating substantial growth in revenue despite facing pricing pressures on its key products, Mounjaro and Zepbound. The company projects revenues between $80 billion and $83 billion for 2026, marking a 25% increase from 2025 at the midpoint. This growth is attributed to strong product performance and strategic maneuvers within their pipeline. Eli Lilly has also made strategic decisions by optimizing its pipeline through dropping three clinical-stage drugs, including a gene therapy acquired via Prevail Therapeutics. This move points towards Lilly's focus on concentrating efforts on more promising candidates within their expansive pipeline. Additionally, Eli Lilly is expanding its GLP-1 franchise beyond metabolic diseases into immunology and inflammation with ongoing clinical trials in conditions such as asthma, psoriatic arthritis, Crohn's disease, and ulcerative colitis. This strategic expansion could lead to novel therapeutic options for chronic inflammatory diseases.Similarly, Bristol Myers Squibb is focusing on new growth drivers amid declining sales of legacy drugs. With $48.2 billion in revenue projected for 2025 largely stemming from newer products, BMS is strategically repositioning itself to maintain momentum amidst market changes.Novartis faces its largest patent expiry challenge but remains optimistic about its trajectory. CEO Vas Narasimhan suggests robust strategies are in place to counteract these patent expiries, indicating a strong focus on innovation and strategic planning to navigate these hurdles. Novartis is also refining its oncology strategy by cutting early-stage cancer candidates while adding new ones focused on promising therapeutics—a broader trend of adopting data-driven approaches to streamline drug development pipelines.Meanwhile, AbbVie continues its stronghold in the inflammatory bowel disease market with its blockbuster immunology drugs Skyrizi and Rinvoq. These products significantly contribute to AbbVie's $61.1 billion revenue, highlighting their commitment to maintaining leadership in immunology despite competitive pressures from rivals like Johnson & Johnson.Astellas has exceeded expectations with its cancer drug Vyloy overcoming a trial setback to quadruple sales in the third quarter fiscal year 2025 results. This success underscores the resilience and potential of innovative oncology treatments even when faced with clinical challenges.In financial markets, Veradermics successfully raised $256 million through its IPO, signaling strong investor interest in biotech firms with promising dermatological applications. Concurrently, Eikon Therapeutics marked the largest biotech IPO since 2024 with a $381 million listing on Nasdaq, reflecting renewed investor confidence in biotech ventures. Industry trends indicate a resurgence of interest in public markets exemplified by Eikon Therapeutics' upsized IPO alongside Veradermics' successful Support the show

4. februar 2026 I denne episoden markerer vi Verdens kreftdag 4. februar med fokus på årets tema "Close the Care Gap". Vi feirer åpningen av Aktiv mot kreft-senter på Campus Radiumhospitalet 4. februar – verdens første kompetansesenter for trening og kreft – med Kong Harald og helseminister Jan Christian Vestre til stede. Vi oppsummerer også den første prisutdelingen for fremragende innsats i kliniske studier, der blant andre Oslo myelomatosesenter, BMS' CAR-T-studie QUINTESSENTIAL-2 og Åslaug Helland ble hedret for sitt arbeid. I nyhetsoppdateringen dekker vi: Circio sin overtegnede emisjon på 65 MNOK, Exact Therapeutics sine positive data fra bukspyttkjertelkreftstudie, Oncoinvent sin utvidede fase 2-studie med fire nye sykehus, PCI Biotech sin planlagte avvikling, og Modernas sterke femårsdata for persontilpasset kreftvaksine – og hva det betyr for Nykode. Til slutt ser vi frem mot Livsvitenskapskonferansen 10.-11. februar i Oslo, med internasjonale tungvektere fra Bayer, Roche, Novo Nordisk og GE HealthCare. I neste episode skal vi ha med oss Erling Nordbø fra Aleap Ventures, et nytt helsefond sm ble satt opp i 2025. Send oss gjerne spørsmål!

If you work across time zones, borders, and cultures, this is the show for you. This is your host Leonardo, welcome to The International Business Podcast. AI can now summarise almost anything in seconds. That's powerful, but it makes it easy to stay at the surface. We get headlines, bullet points, "3 key takeaways", and move on. What's lost is context, nuance, and understanding that changes how professionals think and decide in international business. With this new format, host Leonardo Marra pushes in the opposite direction. Instead of a quick AI overview, he built a long‑form deep dive into Japan after 1945: from World War II defeat to economic miracle, bubble, stagnation, and today's super‑aging, innovation‑driven society.Part 1 traces Japan's path from post‑war devastation through U.S. occupation, state‑guided capitalism, keiretsu networks, export‑led growth, oil shocks, the 1980s bubble, and the "lost decades." It links policy, institutions, and social change to Japan's rise and current challenges.Part 2 shifts to practical insights. Guests who live and work in and around Japan share how firms make decisions, how kaizen and relationships function, how demographics reshape strategy, and what foreign executives consistently misunderstand about the Japanese market.--------⁠Join Leonardo on Patreon for Podcast Archive and Bonus episodes (100+ episodes). ⁠--------With guests:Massimiliano Colonna – Director of Communications, Brookings Institution Governance Studies. MPhil in Modern Japanese Studies from Oxford's Nissan Institute, where he researched the internet's role in Japan's political debate.Waka Someno – CEO of YOUNEEDS Co., Ltd. and SOMENO-YA (Tokyo/Osaka). Provides sales, marketing, and legal support for international companies entering Japan. Over 15 years in B2B sales, DX solutions, and market-entry advisory.Jason Durkee – President, Idea Development (Tokyo); co-founder, Practical Training Transfer. 25+ years helping businesspeople innovate, communicate across cultures, and transfer learning to results. CPTD, ATD Japan director, serves 130+ clients annually across Asia.Neal Jansen – Director, Asia Office, Arkansas Economic Development Commission. CEcD with 20+ years in FDI, trade, and workforce development. Fluent in Japanese, builds long-term partnerships between Arkansas and Asian companies.Brett Jason Lee – Learning and performance professional specializing in Asia Pacific; ICF Professional Certified Coach (PCC). Designs learning solutions focused on behavior change, capability building, and cultural context for Japan and the region.Shaun Rein – Founder & Managing Director, China Market Research Group (Shanghai). Author of five bestselling books on China's economy. Works with Fortune 500s, PE firms, and heads of state. Regular contributor to WSJ, FT, NYT, CNBC, CNN, Bloomberg. Harvard MA.Tom Roberts – Founder, Cranberry Leadership International. "The Expat Whisperer." Former Head of Japan - Neurology at UCB (200 people, ~$1B P&L) and MD/President UCB Korea. Forbes Coaches Council member, helps C-Suite leaders navigate cross-border challenges.Jeff O'Dea – Communication Specialist, Inspiringbiz (Tokyo). Since 2010, helps Japanese professionals communicate effectively in English for global meetings. Clients include BMS, Novartis, MSD, Chugai, Merck, UCB, Softbank.Kelvin Ro – Founder, Kagi Career LLC (Tokyo, 15+ years). Coaches non-Japanese professionals on landing jobs in Japan. Author of Three Ways to Land Your First Job in Japan; ranked #2 non-Japanese LinkedIn creator in Japan (Dec 2024).-----If you work across time zones, borders, and cultures, come on the show to share your story. ⁠Connect with the host Leonardo Marra.

Viviamo in un'epoca in cui l'ingegneria civile e l'architettura hanno raggiunto vette di complessità inimmaginabili solo pochi decenni fa. Le città di oggi sono definite da strutture verticali ad alta densità e da luoghi di intrattenimento sofisticati, progettati per ospitare migliaia di persone contemporaneamente. Eppure, nonostante questi progressi tecnologici, anche l'edificio apparentemente più sicuro potrebbe celare delle insidie per la nostra incolumità. Tragici eventi come l'incendio di Crans-Montana e gli incendi di Hong Kong hanno esposto vulnerabilità critiche nei nostri sistemi di protezione. Ma quali sono le cause di questi fallimenti? E soprattutto, quali sono le nuove tecnologie e approcci che stanno trasformando la sicurezza degli edifici moderni?Nella sezione delle notizie parliamo di Amazon che chiude i negozi senza casse Go e Fresh, dell'aeroporto Heathrow che completa la modernizzazione con gli scanner CT e infine di Google che integra l'IA in Chrome con la Auto Browse.--Indice--00:00 - Introduzione01:05 - Amazon chiude i negozi senza casse (CNN.com, Davide Fasoli)02:19 - London Heathrow adotta gli scanner CT (DDay.it, Matteo Gallo)03:33 - Google introduce l'IA in Chrome (TheVerge.com, Luca Martinelli)05:06 - Quanto sono sicuri gli edifici di oggi? (Matteo Gallo)16:44 - Conclusione--Testo--Leggi la trascrizione: https://www.dentrolatecnologia.it/S8E5#testo--Contatti--• www.dentrolatecnologia.it• Instagram (@dentrolatecnologia)• Telegram (@dentrolatecnologia)• YouTube (@dentrolatecnologia)• redazione@dentrolatecnologia.it--Immagini--• Foto copertina: Jannoon028 su Freepik--Brani--• Ecstasy by Rabbit Theft• Royalty (Don Diablo Remix) by Egzod & Maestro Chives

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory challenges, and strategic investments that are shaping the future of healthcare.Let's begin with Moderna's recent decision to halt its late-stage vaccine trials, a move reflective of a broader trend of vaccine hesitancy in the United States. Moderna's CEO Stéphane Bancel pointed to shifts in government policy and an increasing public skepticism towards vaccines as pivotal reasons for this decision. This development signals a potential slowdown in vaccine research and development investments across the industry. The implications are profound, as vaccine hesitancy could impact public health initiatives and the readiness to tackle future pandemics.In parallel developments, Sanofi is navigating its own set of challenges with its eczema treatment. Despite plans to file for FDA approval for its OX40 blocker following the Phase III COAST 2 trial, results were mixed, echoing earlier data that analysts found underwhelming. This situation highlights the inherent uncertainties in drug development and raises questions about the treatment's potential market success. As Sanofi persists, the broader industry is reminded of the complexities involved in bringing new therapies to market, particularly in dermatology where unmet needs remain significant.Meanwhile, Chinese biotech firm Corxel has secured an impressive $287 million in Series D1 funding to push forward its oral GLP-1 therapy, CX11. This funding will support its mid-stage development in the US and preparations for Phase III studies. The investment underscores a robust interest in GLP-1 therapies known for their efficacy in treating type 2 diabetes and obesity. The competitive landscape for these therapies is heating up, with major players vying for market dominance through novel delivery mechanisms and enhanced patient outcomes. Notably, Novo Nordisk's oral Wegovy is advancing while Eli Lilly's Orforglipron faces delays, highlighting the strategic importance of timely development and market entry in capturing lucrative opportunities within this therapeutic area.On the regulatory front, a notable legislative challenge has emerged with the failure to reauthorize the FDA's rare pediatric disease priority review voucher program for 2024. Advocates are calling for its reinstatement given its critical role in incentivizing the development of rare disease treatments through expedited review processes. Such regulatory changes underscore the delicate balance between encouraging innovation and ensuring rigorous standards, a dynamic that continuously shapes R&D strategies within the industry.In oncology, Bristol Myers Squibb is making headlines with an $850 million investment in Janux Therapeutics' tumor-activated drugs. This significant investment reaffirms BMS's commitment to pioneering cancer therapies that promise better patient outcomes through innovative mechanisms of action. The focus on oncology reflects a broader industry trend towards precision medicine and targeted treatments aimed at improving efficacy while minimizing side effects.As we pivot to manufacturing developments, Lotte Biologics is expanding its capabilities with plans to launch its Syracuse ADC hub by 2026. This expansion aligns with global efforts to enhance manufacturing quality and capacity, crucial factors as biopharmaceuticals become more complex and demand increases.Turning our attention to financial achievements within the industry, Samsung Biologics has reached a historic milestone by becoming the first Korean biopharmaceutical company to surpass a profit threshold of 2 trillion won ($1.36 billion). This accomplishment spotlights the growing influence of contract manufacturing organizations (CMOs) like Samsung BiologicsSupport the show

On this week's episode, Grace Colon, Tim Opler, Graig Suvannavejh, and Eric Schmidt kick off with an overview of Tim's “The Case for Optimism” report, highlighting that macroeconomic conditions will need to stabilize and that M&A is likely to be significant in the coming year. The group also notes how quickly things can shift in biotech, citing recent inconsistencies at the FDA. Next, the co-hosts discuss the reopening of the IPO market after a quiet period, and how this could reshape M&A dynamics and company valuations compared to when acquisitions were the primary exit route. The conversation then turns to recent deals, including GSK's $2.2B acquisition of RAPT Therapeutics for its next‑generation food allergy drug and Janux Therapeutics' up to $850M cancer collaboration with BMS. On the policy front, the co-hosts cover the United States' official withdrawal from the WHO and the FDA's new draft guidance outlining how minimal residual disease and complete response could support accelerated approvals in multiple myeloma. They also highlight Corvus Pharmaceuticals' positive Phase 1 results in atopic dermatitis and the company's stock jump. Tim closes the episode by discussing his recent women's health report and the growing interest and investment in the space. *This episode aired on January 23, 2026.

Werbung *** Diese Folge wurde mit freundlicher Unterstützung der Firma  Bristol Myers Squibb produziert ***   Zwei-gegen-Eins Interview mit Stefan Reininghaus-Janßen von Bristol Myers Squibb: "Wie kommen die prädiktiven Biomarker-Tests als Companion Diagnostic in den Markt?"   Immer wieder kommen im Rahmen der personalisierten Medizin neue Medikamente für bestimmte Indikationen auf den Markt. Von der Idee eines Wirkstoffs bis zu seiner möglichen Implementierung ist es jedoch ein sehr langer Weg mit vielen Zwischenschritten. Hierum geht es in dieser Folge: Wir sprechen im heutigen Zwei-gegen-Eins Interview mit Stefan Reininghaus-Janßen, Medical Lead Precision Medicine bei Bristol Myers Squibb, über prädiktive Biomarker-Tests: es geht u.a. um deren Entwicklung, klinische Validierung mit Studien, die Zusammenarbeit zwischen Diagnostikunternehmen und Pharmaunternehmen, die regulatorischen Anforderungen und den Zulassungsprozess, die Kommerzialisierung sowie Markteinführung.   Ein super spannender Blick hinter die Kulissen…..Sven und ich haben viel gelernt! Aber hört selbst.   Stefan Reininghaus-Janßen war übrigens schon einmal bei Patho aufs Ohr zu Gast. Hier der Link hierzu: https://www.podbean.com/media/share/pb-prst2-138afc1?download=1 Und hier der link zu BMS: https://www.bms.com/de bzw. im Podcast erwähnt zur QuIP und zum vfa: https://www.quip.eu/de_DE/ https://www.vfa.de/.   Wir freuen uns über euer feedback. Kontakt: sven.perner@pathopodcast.de linkedin.com/in/prof-dr-med-sven-perner-6a771b48   christiane.kuempers@pathopodcast.de linkedin.com/in/pd-dr-med-christiane-charlotte-kümpers-279a382b8   Disclaimer: Der Podcast dient ausschließlich allgemeinen Informationszwecken. Die Informationen dieses Podcast sind kein Ersatz für eine professionelle medizinische oder psychologische Beratung, Diagnose oder Behandlung. Die Nutzung der Informationen oder von Materialien, die mit diesem Podcast verlinkt sind, erfolgt auf eigene Verantwortung. Bei gesundheitlichen Fragen oder Beschwerden sollte ein Arzt/eine Ärztin Ihres Vertrauens konsultiert werden.

Podcast: ICS Arabia PodcastEpisode: From Physical Security to OT Cybersecurity (Arabic) | 45Pub date: 2026-01-15Get Podcast Transcript →powered by Listen411 - fast audio-to-text and summarizationJoin us in this new episode of the ICS Arabia Podcast as we sit down with Bassem Ben Amor, a seasoned Physical Security Manager from Tunisia with over 12 years of experience.Bassem shares his journey from managing physical security and BMS systems to transitioning into the world of OT cybersecurity.We discuss his work as a security integrator, his passion for writing articles, and exciting projects he's currently involved in.The podcast and artwork embedded on this page are from ICS ARABIA PODCAST, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

On this week's episode, Chris Garabedian, Paul Matteis, Mike Yee, and Sam Fazeli recap the 2026 J.P. Morgan Healthcare Conference, noting that the biotech outlook for 2026 is broadly positive. Investor sentiment is noted as healthy but not overheated, and from the specialist community, the outlook is similarly upbeat. On the venture side, the M&A landscape also looks strong, with one of the best pre‑JPM financing weeks in at least a decade. The conversation turns to company updates, with Alnylam's 2030 strategy as well as Moderna's cost-cutting initiatives and upcoming vaccine readouts. On the deal front, the group covers AbbVie's $650M partnership with China-based RemeGen on a next‑gen PD‑1/VEGF bispecific antibody. AI developments were another key theme at JPM, including Pfizer's claim that AI contributed to $5.6B in cost reductions. In regulatory news, FDA flexibility, new CMC guidance for cell and gene therapies, and updates on Dr. Makary's CNPVs are overviewed. Next, the co-hosts cover the latest obesity news, including new oral GLP-1s and potential competition from Pfizer and Amgen in the monthly injectables market, as well as BMS and AbbVie's interest in entering the space. The episode concludes with rapid‑fire round of data updates in DMD, gene therapy, myeloma, cystic fibrosis, and Alzheimer's prevention. *This episode aired on January 16, 2026.

Para entender lo que las marcas no te explican. Porque el automóvil está cambiando radicalmente. Nuestra querida jerga de cilindradas, compresión y árboles de levas está siendo sustituida por un nuevo diccionario lleno de siglas que, admitámoslo, muchas veces parecen diseñadas para confundirnos. Hoy no vamos a debatir si el eléctrico es el futuro o no; hoy vamos a diseccionar la tecnología con "ingeniería a tu alcance" para que, cuando leas una ficha técnica, entiendas de verdad qué te están vendiendo. Aquí tienes los pilares fundamentales para entender un coche eléctrico moderno: 1. kW vs. kWh La gran confusión Es la base de todo y donde más gente se pierde. -kW (Kilovatios): Es la POTENCIA. Equivale a lo que antes llamábamos caballos (CV). Para pasar de kW a CV solo multiplica por 1,36. Representa la fuerza del motor o la velocidad de carga. -kWh (Kilovatios-hora): Es la ENERGÍA. Es la capacidad de la batería, equivalente a los litros del depósito de gasolina. Piensa en un cubo de agua: los kWh son el tamaño del cubo (cuánta agua cabe) y los kW son el grosor de la manguera. Tener muchos kWh (batería grande) no garantiza cargar rápido si tu sistema de carga (kW) es lento. 2. El Corazón: Motores Síncronos vs. Asíncronos No todos los "motores de 200 CV" son iguales. Existen dos grandes familias: -Síncronos de Imanes Permanentes (PSM): El rotor gira a la misma velocidad que el campo magnético. Son los reyes de la eficiencia (más del 90%) y ultra precisos, ideales para ciudad. La desventaja es que son caros y pueden generar resistencia al rodar por inercia si no se gestionan bien. -Asíncronos o de Inducción (ASM): El rotor gira algo más lento que el campo magnético. Son robustos y más baratos (sin imanes de tierras raras). Su gran ventaja es que no ofrecen resistencia cuando no se usan, permitiendo ir "a vela" en autopista sin consumo. Muchos coches de tracción total inteligentes usan un motor síncrono en un eje para el día a día y un asíncrono en el otro que solo "despierta" al pisar a fondo. 3. La Química de la Batería Exige saber qué química lleva tu coche, porque determina su vida útil y uso. -NCM (Níquel-Cobalto-Manganeso) / NCA: Son las baterías de alto rendimiento. Ofrecen mucha densidad energética (mucha autonomía en poco peso), ideales para viajes largos y deportivos. Sin embargo, son más caras, inestables térmicamente y sufren si se cargan siempre al 100%. -LFP (Litio-Ferrofosfato): Son las baterías que están democratizando el eléctrico. Son rocas: muy seguras, difícilmente arden, baratas y con una vida útil larguísima (+2.000 ciclos). A diferencia de las NCM, a las LFP debes cargarlas al 100% frecuentemente para calibrar su gestión. Su contra es que pesan más y sufren más con el frío extremo. 4. Voltios y Carga: 400V vs 800V La mayoría de eléctricos funcionan a 400 Voltios, pero los más sofisticados saltan a 800 Voltios. ¿La diferencia? En un sistema de 800V, la electricidad se empuja con más presión (voltaje) y menos intensidad, lo que reduce el calor y permite usar cables más finos. Esto se traduce en cargas ultrarrápidas consistentes, recuperando del 10 al 80% en apenas 18 minutos. Glosario Básico para no perderse: -BMS (Battery Management System): El director de orquesta. Controla temperatura y voltaje de cada celda. Un buen BMS define si tu batería durará 10 años o 3. -Curva de Carga: Olvida el "pico de potencia". Lo importante es la potencia media. Muchos coches tienen un pico alto que cae a los 5 minutos. -Frenada Regenerativa: El motor se vuelve generador. Úsala al máximo en ciudad (One Pedal) y minimízala en autopista para aprovechar la inercia. -Frunk: Maletero delantero, ideal para cables sucios. -WLTP vs. Realidad: Para saber la autonomía real en autopista a 120 km/h, resta un 25-30% a la cifra oficial WLTP. El enemigo es la aerodinámica. -Vampire Drain: El consumo fantasma de tu coche parado (sistemas de vigilancia, conectividad, etc.). Entender un coche eléctrico requiere cambiar el chip: dejamos de mirar cilindros para mirar celdas. Si es para ciudad, busca LFP y eficiencia; si es para viajar, busca aerodinámica, NCM y 800V. La información es poder.

Live Work with Madeleine I'm Helpless! Part 2 of 3 Today, we are pleased to present the exciting conclusion of our work with Madeleine, a loving mother who fears that her eldest daughter might be in mortal danger during her year abroad. Last week, you heard about the T = Testing and E = Empathy phase of the live work with Madeleine, a mother feeling intense panic and helplessness and inadequacy because she fears that her daughter could be in grave danger of abduction and worse. This week, we will focus on A = Paradoxical Agenda Setting, using the Miracle Cure Question, Magic Button, Positive Reframing, and Magic Dial to see if we can melt away her resistance to change. You can see the Emotions table of the Daily Mood Log Madeleine during the Magic Dial portion of the session if you Click Here As you can see, she wanted to reduce her negative feelings somewhat, but thought she still wanted to keep them fairly elevated, since she still sensed that her daughter might be in real danger, and clearly did not want to abandon her. This is one of the significant refinements in TEAM CBT. First, we want to bring the patient's resistance to full conscious awareness. Second, we want patients to full grasp that their negative thoughts and feelings do NOT result from some "defect" or "mental disorder," but rather from what is most beautiful and awesome about them as human beings. After the Magic Button, David and Jill went on to the final, M = Methods portion of the TEAM session, using tools such as Identify and Explain the Distortions, the Double Standard Technique, and the Externalization of Voices, with the Acceptance Paradox, the Self-Defense Paradigm, and the CAT (Counter-Attack Technique). We will, of course, do numerous role reversals to see if we can get Madeleine to a "huge" victory over her many distorted thoughts. You can see the Daily Mood Log Madeleine prepared at the end of the session if you Click Here As you can see, the reductions in negative feelings were dramatic, but in several areas (anxiety, inadequacy, frustration and anger), Madeleine's negative feelings were still minimally elevated. That is one of the reasons we decided to schedule an additional session together several weeks later to see if we could intensify Madeleine's responses to her negative thoughts, and hopefully due some Cognitive Flooding to complete her "treatment." At the end of these show notes, you will find an email from Madeleine after the session that includes her end-of-session scores on the BMS and EOTS. You will also see comments submitted by many participants who attended the webinar live. This email below from Madeleine following the session shows her end of session scores on the Brief Mood Survey as well as the Evaluation of Therapy Session at the end of her session with Jill and David. Hi David, Yes, here are my BMS & ETS score totals after the extended session. Please let me know if you have any questions. A relapse prevention session would be nice; however, I hesitate to accept your offer as you all are so busy. Please know that I am practicing the PTs and keeping the NTs in check for now. Thank you again a million times over

Bob covers John 3: 1-12, where Jesus tells Nicodemus that he must be born again to see the kingdom of God.Mentioned in the Episode and Other Links of Interest:The previous episode in this series, i.e. BMS ep. 396, Installment 9: Cleansing the Temple.Help support the Bob Murphy Show.

Live Work with Madeleine I'm Helpless! Part 1 of 3 Today, we are pleased to present one of our favorite podcast topics—live work with a real human being who is suffering. We will be working with Madeleine, a woman who read a disturbing article while at the hairdresser and freaked out, sensing that one of her daughters might be in mortal danger. This live and unedited session was first presented as part of a free webinar on September 11, 2025. There was no preparation or role-playing—everything was absolutely real and spontaneous, exactly as it evolved in real time. We present Part 1 as our final Feeling Good Podcast for our 2025 season. This is our most powerful and popular type of podcast, and we hope you enjoy it. We also give a big thanks to our courageous "patient," Madeleine. My co-therapist will be Dr. Jill Levitt, a clinical psychologist and Director of Training at the Feeling Good Institute in Mountain View, California. Jill and I greatly enjoy working together as co-therapists when we teach and we typically see our "patient" for an extended, two-hour session. We find that this is the most effective format for teaching, and that way, we can frequently complete a course of therapy in a single session. However, you do not need more than one therapist to do effective TEAM CBT, and you can do it in conventional 50 minute sessions as well. But often, you can do vastly more in a double session. We will not be engaged in an ongoing therapeutic relationship with Madeleine. When we work with therapists, they are doing personal work as a part of their training. We feel that this experience is vital for every therapist who hopes to do world-class TEAM CBT with their own patients / clients. More than 2,000 individuals registered for this workshop. Although the workshop was open to everyone, only 13% of the participants identified as general public, while 87% identified as mental health professionals.  In Part 1, which we present today, we focused on T = Testing and E = Empathy phases of the TEAM session. In Part 2, which you will hear next week, we will focus on A = Paradoxical Agenda Setting and M = Methods. We will also show you the changes in her scores on the Daily Mood Log (DML) and Brief Mood Survey (BMS) from the start to the end of the session, as well as Madeleine's scores on the Evaluation of Therapy Session (EOTS) at the end, including what she liked the most and least about the session. That way, we can see clearly how much improvement there was (or wasn't) during the session, and how Jill and I did in terms of empathy, helpfulness, and other scales that evaluate the patient's view of the session. In Part 3, which you will hear in two weeks, we did more Externalization of Voices along with Cognitive Exposure, since we had some loose ends we wanted to tie up before completing our work with Madeleine. This follow-up session occurred many weeks after the initial session at the workshop, and will also serve as a follow-up to see how Madeleine did in the days following the live work. Part 1 of 3 Our "patient," Madeleine, is a courageous woman who experienced sheer panic after being triggered at the hair salon while reading an article about a young woman who was abducted. Since Madeleine's oldest daughter's is away at college, taking a year abroad, Madeleine realized she could not protect her from predators and freaked out, thinking about all the horrible things that could happen to her. In addition, Madeleine had many self-critical thoughts about ways she thought she had failed her daughter when her daughter was growing up, and worried about her daughter's judgement: She hasn't always made the best decisions about guys she's gone out with, and she's shared everything with me. She says, 'Don't worry mom. I've learned from this.'" At the start of the session, we reviewed Madeleine's scores on the Brief Mood Survey (BMS). This indicated only minimal depression (5/20), with no suicidal urges or anger, but her anxiety was still extremely elevated (18/20). In addition, her Positive Feelings score was only 20 out of 40, with 0 meaning no positive feelings at all, and 40 being the highest possible feelings. However, her Relationship Satisfaction score with her husband was 25 out of 30, which indicates strong satisfaction, with just a little room for improvement. We will ask Madeleine to complete the BMS again, along with the EOTS, so we can see precisely what changed, and by how much, during the session. Our goal, of course, with TEAM CBT, is nearly always to cause a near-complete, or complete, elimination of symptoms during a single, extended therapy session. In addition, we want every patient to have a crystal clear understanding of how and why they got upset, along with how to use the tools that were the most helpful to them in the session. That way, they'll be armed to deal with future relapses, which are inevitable for all human beings. And here's the big point. Our goal in sharing this session with you is so you can feel inspired, and see that rapid recovery really IS possible. And if you're a therapist, we hope that you will feel motivated to learn TEAM CBT so you can significantly improve your outcomes with your own patients. You can see the Daily Mood Log Madeleine prepared just prior to the session if you Click Here The upsetting situation was reading the article about the young abducted woman in the hair salon. On the Emotions table  she indicated that she was feeling sad, down, and unhappy (85%), anxious, frightened and panicky (100%), inadequate (100%), frustrated (90%), and angry and upset (100%). These extremely high ratings tells us that Madeleine's negative feelings were about as intense as a human being can experience. Although your life is undoubtedly very different from Madeleine's, perhaps you, too, have felt panic and helplessness when you thought the life of a loved one might be in danger. Madeleine generated several additional negative Thoughts during the empathy phase of the session, including, I'm totally responsible for how she's turned out. 95% I was not present enough for her. 95% She may not trust that I'm there for her. 60% She's anxious and insecure and a people-pleasure, and she's also perfectionistic, and it's all my fault. 75% I should have been more sensitive when she was growing up. I expected too much. 100% Again, if you're a parent, you may have had similar negative thoughts about your own parenting. I know that I have! During the Empathy phase, Madeleine described her horrors when reading the article at the hairdresser's, with thoughts of Natalie Hollaway's brutal murder as well as other women who were abducted and murdered. Madeleine explained that she and her husband both married late, and felt somewhat insecure as parents: "It wasn't easy having children late in life. . . .  When our first baby was born, the milk was not coming down. My daughter would look deep into my eyes, and I had the thought, 'I'm letting my daughter down.'" She said she had a rough time when she was growing up and her parents got divorced: "My heart was broken, and I had to learn to be strong. I had to learn not to let so much emotion through. I had to learn how to keep guys at arm's length. I had to protect myself from getting hurt." She said that wanted her daughters to grow up being strong and independent, but as she reflects back, she thinks she may have failed them and not provided enough warmth and support. Our goal during E = Empathy is not to help or even try change anything, but simply to go with our patients to the gates of hell, so they can vent, cry, and express their deepest and most private feelings. At the end of the Empathy portion of the session, we asked Madeleine to grade us on the three key elements of empathy, using letter grades: How accurately did we understand how you were thinking? How accurately did we understand how you were feeling inside? To what extent did we convey the spirit of trust, warmth, and acceptance? She gave us 3 A's, indicating it was time to move on to A = Paradoxical Agenda Setting, which you will hear next week. We will want to find out what Madeleine might want help with. We will also try to melt away her resistance to change using the Miracle Cure Question, the Magic Button, Positive Reframing, and the Magic Dial.    Why would we anticipate resistance? After all, Madeleine is asking for help. But remember, the desire for change cannot always be take for granted in anyone. Nearly all of us have mixed feelings about change. After all, a loving and concerned mother might NOT want to stop worrying about a beloved daughter who seems to be in grave danger! But if you deal with this resistance in a compassionate way, you may open the door to the possibility of rapid healing when you come to the M = Methods portion of the session. We can check it out at the exciting conclusion of the work with Madeleine next week!

It's the Weekend Baby!Close the laptop, answer the last email, and tell the boss to…. Well, you may want to return to a job on Monday but until then, it's your time to express yourself through music and dance. This collection of songs tells that story of short-term emancipation of those structured roles. So let loose, have fun, and have something to talk about on Monday.For now – you're Livin' for the Weekend with BMS!This episode includes Cherrelle, The S.O.S Band, The Gap Band, Montell Jordan, K-OS and many others.Let's take this ride together and remember when music was Music!1. SATURDAY LOVE/CHERRELLE2. STOMP/BROTHER'S JOHNSON3. PARTY TRAIN/GAP BAND4. NIGHT CRUISING/The Bar-Kays5. HERE I GO AGAIN (ANOTHER WEEKEND)/KWICK6. LOOKOUT WEEKEND/DEBBIE DEB7. WEEKEND/FIBRE FOUNDATION8. NO WORRIES/NOEL GOURDIN (HILL ST. SOUL)9. GOOD TIME/CHARLIE WILSON10. THIS IS HOW WE DO IT /MONTELL JORDAN11. SATURDAY/DE LA SOUL12. THE CLUB/SIR PIERS13. LOOKIN' FOR LOVE/FAT LARRY'S BAND14. SUNDAY MORNING/K-OS15. BACKYARD PARTY/R. KELLY16. WEEKEND GIRL/S.O.S. BAND17. GOOD TIMES/CHIC

Dr. Pedro Barata and Dr. Ravin Garg discuss strategies to increase trial representation, including leveraging trial navigators and prioritizing pragmatic trial models, as featured in the ASCO Educational Book article, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care." TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast from ASCO featuring compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I am a medical oncologist at University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I am also the associate editor of the ASCO Educational Book. We know that in recent years, the oncology community has increasingly prioritized the need to modernize clinical trial eligibility, reduce patient burden, and enhance diversity in trial participation. On that note, today we will be speaking about ways to enhance access to clinical trials with Dr. Ravin Garg. He is a hematologist oncologist at Maryland Oncology Hematology and also an assistant professor of oncology at Johns Hopkins Hospital in Baltimore. Dr. Garg is also the co-author of a fantastic paper in the ASCO Educational Book titled, "Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care."  Dr. Garg, welcome. Thanks for being here, and congrats on your paper. Dr. Ravin Garg: Thank you for having me, Pedro. I am excited to be here. Dr. Pedro Barata: [KI1]  Your paper is a wonderful, multidisciplinary piece that actually features perspectives from the different stakeholders, right? The patient advocacy, industry, community practice, and academia about these challenges in making trials more available. This podcast is a wonderful platform. It reaches out to a lot of folks within our community. So, I will start by asking you the obvious. Why do you think it is a must read for our community, for our listeners? Dr. Ravin Garg: So Pedro, thanks again for inviting me. You do a great job with these podcasts.  So, I think first and foremost, oncologists right now are under a lot of stress, just in terms of clinical volume. There is concern for research money, and how we get the best care for our patients. So I think this article is very important because it helps bring together, as you had mentioned, the stakeholders throughout academic to community practice and everywhere in between, and try to find how, as a team with different oncologists who partake in different aspects of oncology, can come together to streamline the process to try to get our patients on trials, or certainly have them have availability of trials, just if they are interested in going on them. Being in practice, we have had several challenges that we can talk about throughout this podcast, but I think it is a very important paper because it recognizes that at the end of the day, it takes a team effort for all of us in academics, community, industry, and pharmaceuticals to really come together as a team to really help put forth the trials for our patients. Dr. Pedro Barata: So, from the perspective of a community oncologist, how do you put together, or maybe you can describe some of the challenges that you see to increase trial participation in the community? Dr. Ravin Garg: Yes, Pedro, that is a great question, and it is something that I keep on thinking about and trying to find ways to be better at it myself. But I will say some of the challenges as a community doctor that I have seen for myself and talking to other colleagues. Number one, I do think there is a lot of stress on doctors in the community in general, Pedro. Oftentimes we are tasked to see a wide smorgasbord of patients, so we may not have the luxury of being a specialist in any particular tumor subtype. Like oftentimes, we will have to see lung cancer, the next one will be breast cancer, the next one could be CML, the next one could be thrombocytopenia. And as you know better than I do, Pedro, the field in each one of these disciplines is changing so rapidly: molecular genomics, radioligand treatments, different imaging tests, MRD testing for some of our hematologic malignancies. And I think one challenge we have in community is just keeping up with the basics of Oncology 101. In the process of doing that, it can be very difficult to sometimes remember that we have very exciting trials available for our patients. So, I think a lot of it is the day in and day out of being an oncologist is so taxing at times that oftentimes a research trial is not the first thing in our head space when we see a patient. I think number two, Pedro, at least in the community, and perhaps this is with academics too, is that we are bombarded, I would say, by a lot of messaging these days. We have in-baskets to go through, labs to go through, things of that nature. And in the process of a patient visit, seeing them, doing an exam, taking a history, trying to go over the NCCN guidelines on best practice for how to manage their care, at least for me at times, it is very hard to remember, "Hey, there might be a great trial available, whether within our network or maybe partnering with an academic center." So getting through a day can be fraught with a lot of peril and just difficulties, I would say. And I would say number three, Pedro, at least as, you know, I am in a private practice where I do see a wide range of benign and malignant hematology and solid tumors, so I would not call myself a specialist. And I think the challenge with that, at least for trials, Pedro, is that when you are a specialist or perhaps you are focusing on a couple of disease subtypes, you become more of an authoritative voice in those types of tumors, and you might be more aware of the trials within your network or perhaps in proxy with an academic center that you can offer your patient. So I think when sometimes we spread ourselves too thin, it can be very hard to be a thought leader, if you will, in a particular subtype of a malignancy, let's say, and maybe not be aware of a trial that could be really well-suited for your patient. In terms of ideas that myself and colleagues have had in terms of helping mitigate against some of these, I would say, setbacks or issues in the practice for trial enrollment, some of the things we have talked about, Pedro, is, number one, is we do partner with academic centers. So we live here in Maryland. We have several really fantastic academic centers. So, you know, oftentimes, not just within our practice of Maryland Oncology Hematology, we have a lot of great trials available here too, for certain, but in addition to that, we will often times work with doctors at Georgetown, Johns Hopkins, and Maryland if they have a compelling trial that we do not have within our network. It is really of the patient's interest, Pedro, to reach out to them in a collaborative manner to see if they have a trial that might be really compelling for your patient. So I do find myself collaborating a lot with colleagues in, like talented like yourself in academics. You know, I think you do a lot of GU malignancies. So as an example, like partnering with colleagues who are GU experts and say, "Hey, we have a patient with stage IV renal cell. These are the standard options I know, but are there any trials that you might have available?" I think the other thing that has been very helpful for us is having navigators within research, Pedro. Like as an example, what has really helped the uptake of trial enrollment for our center in Annapolis is having a research navigator because often times what they can do is, a priori, Pedro, before you see the patient and you are kind of formulating a standard of care treatment plan perhaps, they might tug you on the shirt and say, "Hey, we have a great trial here through Sarah Cannon, or there might be something else out there." And being aware of that when you go into a patient's room really provides a nice arena, if you will, to go and say, "The standard of care is here, but hey, we have a trial option that might be well suited for you, maybe perhaps even better, that we can talk about, too." So having research support in the community is really a huge boon, I think, Pedro, for us to really increase our enrollment for patients onto trials. Dr. Pedro Barata: Yes, I really love that, Ravin. So, let me switch gears a bit. I would love for you to talk a little bit about patient advocacy because they do play a huge role in cancer, and they address many barriers. How do you think we should leverage the patient advocacy groups to reduce patient burden and maybe have them really leverage patient advocacies to improve representation in clinical trials? What do we think we can do more? Dr. Ravin Garg: Oh, Pedro, I think they are very critically important. As a clinical oncologist now, and I would say this is for anyone in the field of medicine, you are exactly right. I think patients are bombarded by information. There are a lot of things online, whether it be TikTok, Facebook, Google, Yahoo, and people really just have a lot of information given to them. And some of it is fact driven, and some of it is not, Pedro. And oftentimes, I do think there can be at times a mistrust with some medical personnel. I think we are in an era where we are seeing that to some degree with some attributes of medicine. And I think of it as an opportunity for education for the patient and for myself as a physician. And I think patient advocates, to your point, which was well taken, serve as a bridge to both. And what I mean is that, you know, patient advocates are wonderful. They are, I think, outstanding communicators. They almost are a neutral party, Pedro, where many patients feel that they are an independent source of information that is free of bias, if you will. They are there to provide support, emotional support, scientific support for patients so they can make an informed decision. So, in terms of our practice right now, patient advocates is something that we are evolving in that capacity, I would say, Pedro. I think now more than ever, having more people as bridges of communication with care providers along with patients is of critical importance. And I would venture a guess, and I think this has been published, where patient advocates really can help tremendously in familiarizing patients with trials and what they are all about and maybe clear up some misconceptions of what trials, what the mission of trials are. Because I do think some patients, at least I have had a few over the years, where when they hear the term trial, they almost think they are being experimented upon, when, in point of fact, they could really help advance their care. That messaging along the way for some can may be mixed up a little bit. And so I think patient advocates is a really great way to offer more information for patients with a source they find very independent and trustworthy, if you will. And it can really help expedite, and I think make a more fruitful conversation for care providers, whether academic or community, and they might be more open-minded in terms of enrolling onto a trial. Dr. Pedro Barata: Wonderful. Yes, I agree. I agree with you completely.  So let's focus a little bit now on the folks designing the studies. We usually call them the sponsors. It might be an academic sponsorship, if you will, but we can also have pharma being the sponsor of a study. The angle from an academic design, it is not necessarily the same as what happens when we have pharma. And from that angle, how do you think a more inclusive research can be promoted? Dr. Ravin Garg: Oftentimes with trials, I think keeping them simple, as simple as we can. And what I mean by that is, often times for trials, Pedro, even for care providers who are enrolling, it can be daunting when there are a lot of different things involved, particularly, let's say, for investigator sponsored, which are incredibly brilliant science, incredible, but it can be a little bit daunting for patients and even the referring physician to talk about getting translational specimens, imaging, traveling to certain centers to get scans and biopsies and even different diagnostic testing like PSMA testing for, you know, prostate cancer. And it can, I think, be very intimidating for patients in terms of what might be required of him or her to enter onto a trial. Like, "This is not what I signed up for. This is laborious. This is a full time job for me. Do I have to pay for parking to go to a city? Do I have to pay for these imaging tests? And do I have to stay in a place for my family to enroll onto a trial?" So I think keeping trials as simple as possible, but yet cull the data we need as investigators where we can really advance the care, hopefully get approval for a drug, but also learn more about the medication and how it works for our patients. So I think simplifying language for trial is very important. I know when I have gone over studies for patients, Pedro, if it is a voluminous amount of information, they can right away get very intimidated. "Like, oh my goodness, this is like a term paper for college again," you know? I am joking, but you know, keeping language simplified is very important, I think, number one. And I feel that sometimes when they are asked to do a lot of different diagnostic testing, which is very important for translational work, I 100% understand, but I do think sometimes patients can get a little bit off put, if you will, and frustrated with the whole process of doing it. The second thing for our patients, Pedro, that they have mentioned to us when we put them on trials, not just within our own site but elsewhere, is that it takes a lot of time in terms of collecting information, perhaps a washout period from their last standard of treatment prior to enrollment onto a study. Many patients, Pedro, as you know better than I do, are in maybe crisis in terms of their health and their cancer might be growing, promulgating out of control, and they worry about not being able to expeditiously start onto a treatment, onto a trial. So that can lead to a lot of frustration. And one thing that you brought up, which was outstanding for me, is the enrollment criterion for some of our patients is felt to be somewhat strict. We have had some patients who may have had a remote history of a stage I malignancy that was by all accounts in remission, you know, let's say 4 or 5 years in the past, and the risk of recurrence at this point would be incredibly low, but they may not be able to enter onto a study because of some stringent criterion put forth. And that can be a little bit frustrating. In fact, I have had one or two patients who, as an example, with kidney issues, but the GFR was about 60, like right near a cutoff that oftentimes, as you know, we use where you can get into trial or not. And you know, if they are at 58, as an example, and otherwise they are a picture of health, a great candidate for a trial that will likely advance their care, and if the entry criterion is too stringent, that might be a lost opportunity for all parties involved, all stakeholders, if you will. I do appreciate the criterion for entry onto studies cannot be too liberalized. You have to have a certain baseline, but there is a little bit of a gray area and tension, of sorts, if you will, where the patient has a comorbid illness that is a disqualifying offense, but in practicality, perhaps it shouldn't be, especially if they are motivated and there is an opportunity to really advance their care. We have run into, not often, but sometimes in the past, I should say, where patients have been very off put because we try to get them onto a study and there may have been a particular feature or attribute in their underlying care that they couldn't get onto it. So I think having a little bit more thoughtfulness, perhaps, in terms of entry criterion and practicality, if you will, I think would really help enrollment onto studies. Dr. Pedro Barata: Really well said. Is there anything else that you would like to tell our listeners before we wrap up the podcast today? Dr. Ravin Garg: I would say just macroscopically speaking, it is really an honor to be an oncologist. I think I speak for both of us. Anyone listening who is thinking about the field, it is tremendous. Just the research, the bravery of our patients, and the thoughtfulness of our scientists like Pedro and translationalists and clinical trialists is really awe inspiring. So I have really loved this field. I will say from a trial perspective, we really need to enter as many patients as we can onto trials because the science is so brilliant now, the genomic underpinnings of the tumor, we are making great strides as a team of clinicians and scientists, translationalists. So the more that we can get people onto trials and get approved drugs, it is going to help them out in the end. So I think it is such an important time for all of us to come together as a community, find the best way to help our patients out. And clinical trials have to be at the forefront of how we can continue to advance care for our patients. Dr. Pedro Barata: Yeah, no Ravin, I really agree with you. We really need to increase access to clinical studies, and actually your paper is a great step in that direction by raising awareness, bringing up solutions, and again, collaboration, collaboration, collaboration is really a multidisciplinary effort to accomplish that.  Thank you so much for sharing your fantastic thoughts and insights with us. Dr. Ravin Garg: Thank you, Pedro. I am- you do a wonderful job with these podcasts. I am really honored to meet you and to be part of this. Dr. Pedro Barata: And thank you to our listeners for your time today. I encourage you to check out Dr. Garg's article in the 2025 ASCO Educational Book. We will post a link to the paper in our show notes. And please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:          Dr. Pedro Barata   @PBarataMD    Dr. Ravin Garg Follow ASCO on social media:          @ASCO on X      ASCO on Bluesky     ASCO on Facebook       ASCO on LinkedIn       Disclosures:       Dr. Pedro Barata:   Stock and Other Ownership Interests: Luminate Medical   Honoraria: UroToday   Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon   Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas   Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck    Dr. Ravin Garg: Patents, Royalties, Other Intellectual Property: Creator, editor, and writer of hemeoncquestions.com  

On this week's episode, Josh Schimmer, Brian Skorney, Paul Matteis, and Graig Suvannavejh share their outlook for the biotech industry in 2026, including a lively discussion on IPO market and predictions for what to expect next year. The discussion then shifts to Washington, where Tracy Beth Høeg has been appointed acting CDER director -- the fifth person to lead CDER this year -- following Richard Pazdur's sudden retirement and ongoing staffing volatility at the agency. Next the co-hosts mention the FDA's moves to speed up drug approvals, the plausible mechanism pathway, and latest with vaccine policies. The FDA's final minutes from a pre-BLA meeting with UniQure and the implications for the broader gene therapy landscape are also discussed. Capricor's positive DMD cell therapy results are also highlighted, reviving hopes for FDA approval. The conversation shifts to data news, including BMS' update on the ADEPT-2 study readout for Cobenfy in Alzheimer's disease psychosis, which the co-hosts read as a net positive. Praxis Medicine's positive Phase 2 results for its seizure drug and ongoing FDA discussions, and Janux Therapeutics in prostate cancer. Otsuka pricing Voyxact at $390K a year is briefly mentioned. The episode concludes with excitement for upcoming conferences including ASH and JPM. *This episode aired on December 5, 2025. 

1. THE BACKSTORY: A NIGHT OUT + A DAREMan goes out drinking with friends 30 years ago.Friends dare him to swallow a plastic cigarette lighter.Hosts joke:“That's smart.”“How do you just assume it passes? Wouldn't you notice?”Conversation about what would happen if you swallowed something that big.Banter about whether anyone checks their BMs that closely.“A lighter? That would hurt coming out!” 2. THE DISCOVERY — 30 YEARS LATERNow 67 years old, the man experiences abdominal pain and bloating.He goes to the doctor for scans.Doctors find a foreign object but can't identify it.Emergency procedure attempted, but removal is difficult:Object is smooth and slippery.They can't grasp it easily. 3. THE BIG REVEALDoctors show the man the scan images.Man realizes: “Oh my gosh…30 years ago, I swallowed a lighter during a dare!”He had assumed it passed through his system at the time—but it didn't. 4. REMOVAL + SHOCKING DISCOVERYDoctors finally remove the lighter during an endoscopy.They notice:The lighter's exterior was corroded by stomach acid.But it still had gas inside.And yes…they try it.The lighter still works — after 30 years inside a human stomach. 5. HOST REACTIONS & HUMOR“Unbelievable.”Jokes about how he didn't notice for 30 years.Banter about blaming stomach aches on “bad Chinese food.”Discussion about whether people in China say “I had bad Chinese food.”Reactions to how shocking it is that the lighter was still functional.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Economist Steve Landsburg gives a presentation based on his new book, which uses intuitive analogies to really explain the slowdown in time and other odd implications of the theory of special relativity.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.Order Steve Landsburg's books.A great "Mechanical Universe" episode showing Lorentz transformations with intuitive animations.BMS interview with Landsburg on the math genius Grothendieck.Help support the Bob Murphy Show.

 BMS 70s Mack IIIWe are going back to the early to mid-70s, when afros, platform shoes, and creative hand shaking were all the rage. It was a time of fun and self-pride within the black community, but it was also a time of despair and self-abuse due to the conditions of the nation.I choose to remember the good times, so let's take this trip together and enjoy the golden era of Black Music.DJ Rhythm Dee hosts a recurring segment known as the Black Magic Sounds. The show will feature the smooth grooves of Neo-Soul, Funk, R&B, Jazz, as well as Disco, Soulful House, Slow Jams, Reggae, and anything that moves you. It's all about feeling the music and hearing some tracks that were forgotten or entirely new to you.Featuring Curtis Mayfield, The Chi-Lites, The Meters, The Moments, Millie Jackson, and much more!PLAYLIST1. Superfly/Curtis Mayfield2. Across 110th Street (Part 2)/Bobby Womack3. Psychedelic Shack/The Temptations4. Scorpio/Dennis Coffey & The Detroit Guitar Band5. Seven Minutes of Funk/The Whole Darn Family6. It's Just Begun/ The Jimmy Castor Bunch7. The Breakdown - Pt. 1/ Rufus Thomas8. I've Got So Much Trouble On My Mind/ Sir Joe Quarterman & Free Soul9. Trouble Man/Marvin Gaye10. Whatcha See Is Whatcha Get/The Dramatics11. You're The Reason Why/The Ebonys12. I Cry/Millie Jackson13. Do It Baby/The Miracles, Billy Griffin14. Who Is He & What Is He To You?/Creative Source15. Hand Clapping Song/The Meters16. Brothers On The Slide/Cymande17. Flying High/Stefano Torossi18. Got The Love/Average White Band19. If You Want Me To Stay/Sly & The Family Stone20. Stoned Out Of Mind/The Chi-Lites21. Sexy Mama/The Moments

Keith Smith is founder of the Surgery Center of Oklahoma. He returns to the podcast to summarize his recent testimony on medical costs.Mentioned in the Episode and Other Links of Interest:The YouTube version of this interview.The CSPAN video of the testimony.The Surgery Center of Oklahoma. The Free Market Medical Association (FMMA). Matt Ohrt's appearance on the BMS.The Tuttle Twins Academy (with Black Friday discount).Help support the Bob Murphy Show.

Audio roundup of selected biopharma industry content from Scrip over the business week ended November 21, 2025. In this episode: obesity beyond GLP-1s; biotech leaders bullish as M&A heats up; BMS's milvexian setback; clinicians on evolution of MASH treatment; and Japan H1 results mixed. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-MXUR6OEDNNAEPPTTZ4YZKH55SU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

BMS Episode 121: Rainy DazeHello, my BMS listeners, this episode will be a mood setter. Think of those days and nights when the rain is coming down but rather than lament, the sound of those raindrops puts you in a daze. Instead of gloom it brings a freshness to the air and a cleansing of your soul. Think of those times when you were with the one you love or reflecting on what could have been.That's what this episode is all about.We feature Sade, Anita Baker, Toni Braxton, Maysa, Farnell Newton, and many more!Remember when music was Music!PLAYLIST1. Making Love In The Rain/Herb Alpert2. Rain On Me/Ashanti3. In The Rain/Keith Sweat4. Just Another Day/Queen Latifah5. Mood For You f/MC Lyte/Lala Hathaway6. I Got You/Mike Champion7. Only You/Tiffany Paige, Sorry Drummer8. Long As I Live/Toni Braxton9. No More Rain (In This Cloud)/Angie Stone10. Pouring Rain/Maysa11. Been So Long/Anita Baker12. Everything is Clear/Farnell Newton13. I Wish It Would Rain/The Temptations14. Walkin' In The Rain With The One I Love/Love Unlimited15. Give It Up/Sade16. Afrodub/The Smoke Orchestra17. Maputo/Bob James, David Sanborn18. Honey - Ron Trent's Honey Mix/Erykah Badu

Meat nerds, assemble. Evan and Tyler sit down with Dr. Phil Bass—associate professor of Meat Science at the University of Idaho, meat cutter since childhood, and all-around legend—to geek out on what actually makes beef great. Fresh off judging the American Wagyu Association's “Best Steak in America” competition together, we dive into BMS scoring (yes, those 14s and 15s), why the USDA grade tops out too early for Wagyu, and what “quality” really means across tenderness, flavor, and juiciness.We get into grass-finished vs. grain-finished (and why consistency matters), the truth about antibiotics and labels, how to shop smarter at the butcher counter, and why the future likely belongs to Wagyu crossbreeding. Plus: the magic of dry-aging, the umami bomb that is koji, myth-busting on Wagyu fat (hello oleic acid), and quick detours into Piedmontese, flat iron “meat jelly,” and why ribeye off the 5th rib slaps.In this episode:Judging ultra-marbled Wagyu & reading the Japanese BMS 1–12USDA vs. AUS vs. JPN grading—should there be one global standard?Grass vs. grain: flavor, texture, and reliabilityDry-aging, koji rubs, and regional mold “terroir”Labels, antibiotics, and how to actually talk to your butcherThe next decade of Wagyu (hello, F1 crosses)Dr. Bass's pod: meatspad.com • Book: It's Not a Cow (available on Amazon)Hit play, get smarter, then go eat something worthy.

Dr. Pedro Barata and Dr. Aditya Bagrodia discuss the evolving landscape of testicular cancer survivorship, the impact of treatment-related complications, and management strategies to optimize long-term outcomes and quality of life. TRANSCRIPT:  Dr. Pedro Barata: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. We all know that testicular cancer is a rare but highly curable malignancy that mainly affects young men. Multimodal advances in therapy have resulted in excellent cancer specific survival, but testicular cancer survivors face significant long term treatment related toxicities which affect their quality of life and require surveillance and management. With that, I'm very happy today to be joined by Dr. Aditya Bagrodia, a urologic oncologist, professor, and the GU Disease Team lead at UC San Diego[KI1]  Health, and also the lead author of the recently published paper in the ASCO Educational Book titled, "Key Updates in Testicular Cancer: Optimizing Survivorship and Survival." And he's also the host of the world-renowned BackTable Urology Podcast. Dr. Bagrodia, I'm so happy that you're joining us today. Welcome. Dr. Aditya Bagrodia: Thanks, Pedro. Absolutely a pleasure to be here. Really appreciate the opportunity. Dr. Pedro Barata: Absolutely.  So, just to say that our full disclosures are available in the transcript of this episode.  Let's get things started. I'm really excited to talk about this. I'm biased, I do treat testicular cancer among other GU malignancies and so it's a really, really important topic that we face every day, right? Fortunately, for most of these patients, we're able to cure them. But it always comes up the question, "What now? You know, scans, management, cardio oncology, what survivorship programs we have in place? Are we addressing the different survivorship piece, psychology, fertility, et cetera?" So, we'll try to capture all of that today. Aditya, congrats again, you did a fantastic job putting together the insights and thoughts and what we know today about this important topic. And so, let's get focused specifically about what happens when patients get cured. So, many of us, in many centers, were fortunate enough to have these survivorship programs together, but I find that sometimes from talking to colleagues, they're not exactly the same thing and they don't mean the same thing to different people, to different institutions, right? So, first things first. What do you tell a patient perhaps when they ask you, "What can happen to me now that I'm done with treatment for testicular cancer?" Whether it's chemotherapy or just surgery or even radiation therapy? "So, what about the long term? What should I expect, Doctor, that might happen to me in the long run?" Dr. Aditya Bagrodia: Totally. I mean, I think that question's really front and center, Pedro, and really appreciate you all highlighting this topic. It was an absolute honor to work with true thought leaders and the survivorship bit of it is front and center, in my opinion. It's really the focus, you know, we, generally speaking should be able to cure these young men, but it's the 10, 15, 20 years down the way that they're going to largely contend with. The conversation really begins at diagnosis, pre-education. Fortunately, the bulk of patients that present are those with stage one disease, and even very basic things like before orchiectomy, talking about a prosthetic; we know that that can impact body image and self esteem, whether or not they decide to receive it or not. Actually, just being offered a prosthetic is important and this is something, you know, for any urologist, it's kind of critical. To discussing fertility elements to this, taking your time to examine the contralateral testicle, ask about fertility problems, issues, concerns, offer sperm banking, even in the context of a completely normal contralateral testicle, I think these things are quite important.  So if it's somebody with stage one disease, you know, without going too far down discussing adjuvant therapy and so forth, I will start the conversation with, "You know, the testes do largely two things. They make testosterone and they make sperm." By and large, patients are going to be able to have acceptable levels of testosterone, adequate sperm parameters to maintain kind of a normal gonadal state and to naturally conceive, should that be something they're interested in. However, there's still going to be, depending on what resource you look at, somewhere in the order of 10-30% that are going to have issues. Where I think for the stage one patients, it's really incumbent upon us is actually to not wait for them to discuss their concerns, particularly with testosterone, which many times can be a little bit vague, but to proactively ask about it every time. Libido, erectile quality, muscle mass maintenance, energy, fatigue. All of these are kind of associated symptoms of hypogonadism. But for a lot of kids 18-20 years old, it's going to be something insidious that they don't think about. So, for the stage one patients, it absolutely starts with gonadal function. If they are stage two getting surgery, I think the counseling really needs to center around a possibility for ejaculatory dysfunction. Now, for a chemotherapy-naive, nerve-sparing RPLND, generally these days we should be able to preserve ejaculatory function at high volume centers, but you still want to bring that up and again kind of touch base on thinking about sperm banking and so forth before the operation, scars, those are things I think worth talking about, small risk of ascites. Then, I think the intensity of potential long term adverse effects really ramps up when we're talking about systemic therapy, chemotherapy. And then there's of course some radiation therapy specific elements that come up. So, for the chemotherapy bits of it, I really think this is going to be something that can be a complete multi-system affected intervention. So, anxiety, depression, our group has actually shown using some population resources that even suicidality can be increased among patients that have been treated for germ cell tumor. You know, really from the top down, tinnitus, hearing changes, those are things that we need to ask about at every appointment. Neuropathy, sexual health, that we kind of talked about, including ED (erectile dysfunction), vertigo, dizziness, Raynaud's phenomenon, these are kind of more the symptoms that I think we need to inquire about every time. And what we do here and I think at a lot of survivorship programs is use kind of a battery of validated instruments, germ cell tumor specific, platinum treated patient specific. So we use a combination of EORTC questions and PROMIS questions, which actually serves as like a review of systems for the patient, also as a research element. We review that and then depending on what might be going on, we can dig into that further, get them over to colleagues in audiology or psychology, et cetera.  And then of course, screening for the hypertension, hyperlipidemia, metabolic syndrome with basically you or myself or somebody kind of like us serving, many times it's the role of the PCP, just making sure we're checking out, you know, CBC, CMP, et cetera, lipid parameters to screen for those kind of cardiac associated issues along with secondary malignancies. Dr. Pedro Barata: So that's super comprehensive and thorough. Thank you so much. Actually, I love how you break it down in a simple way. Two functions of the testes, produce testosterone and then, you know, the problem related to that is the hypogonadism, and then the second, as you mentioned, produce sperm and of course related to the fertility issues with that.  So, let's start with the first one that you mentioned. So, you do cite that in your paper, around 5-10% of men end up getting, developing hypogonadism, maybe clinical when they present with symptoms, maybe subclinical. So, I'm wondering, for our audience, what kind of recommendations we would give for addressing that or kind of thinking of that? How often are you ordering those tests? And then, when you're thinking about testosterone replacement therapy, is that something you do immediately or are there any guidelines into context that? How do you approach that? Dr. Aditya Bagrodia: So, just a bit more on digging into it even in terms of the questions to ask, you know, "Do you have any decrease in sexual drive? Any erectile dysfunction? Are your morning erections still taking place? Has the ejaculate volume changed? Physically, muscle mass, strength? Have you been putting on weight? Have you noticed increase in body fat?" And sometimes this is complicated because there's some anxiety that comes along with a cancer diagnosis when you're 20, 30 years old, multifactorial, hair loss, hot flashes, irritability. Sometimes they'll, you know, literally they'll say, "You know, my significant other or partners noticed that I'm really just a little bit labile." So I think, you know, there's the symptoms and then checking, usually kind of a gonadal panel, FSH, LH, free and total testosterone, sex hormone binding globulin, that's going to be typically pretty comprehensive. So if you've got symptoms plus some laboratory work, and ideally that pre-orchiectomy testosterone gives you some delta. If they started out at an 800, 900, now they're 400, that might be a big change for them. And then, when you talk about TRT (Testosterone Replacement Therapy) recommendations, you know, Pedro, yourself, myself, we're kind of lucky to be at academic centers and we've got men's health colleagues that are ultra experts, but at a high level, I would say that a lot of the TRT options center around fertility goals. Exogenous testosterone treats the low T, but it does suppress gonadal function, including spermatogenesis. So if that's not a priority, they can just get TRT. It should be done under the care of a urologist, a men's health, an endocrinologist, where we're checking liver chemistries and CBCs and a PSA and so forth. If they're interested in fertility preservation, then I would say engaging an endocrinologist, men's health expert is important. There's medications even like hCG, Clomid, which works centrally and stimulate the gonadal access. Niche scenarios where they might want standard TRT now, and then down the way, 5, 7 years, they're thinking about coming off of that for fertility purposes, I think that's really where you want to have an expert involved because there's quite a bit of nuance there in recovery of actual spermatogenesis and so forth.  To kind of summarize, you got to ask about it. Checking it is, is not overly complicated. We do a baseline pre-orchiectomy and at least once annually, you can tag it in with the tumor markers, so it's not an extra blood draw. And if they have symptoms of course, kind of developed, then we'll move that up in the evaluation. Dr. Pedro Barata: Got it. And you also touch base on the fertility angle, which is truly important. And I'm just curious, you know, a lot of times many of us might see one, two patients a year, right, and we forget these protocols and what we've got to do about that.  And so I'm interested to hear your thoughts about when you think about fertility, and how proactive you get. In other words, who do you refer for the fertility clinic, for a fertility preservation program? You know, do all cases despite getting through orchiectomy or just the cases that you're going to, you know you're going to seek chemotherapy at some point? What kind of selection or it depends on the chemo, like how do you do that assessment about the referral for preservation program that you might have available at UCSD? Dr. Aditya Bagrodia: Yeah, I mean I feel really fortunate to sit on the NCCN Testis Cancer Guidelines. It's in there that fertility counseling should be discussed prior to orchiectomy. So 100% bring it up. If there are risk factors, undescended testicles, previous history of fertility concerns, atrophic contralateral testicle, anything on the ultrasound like microlithiasis in the contralateral testicle, you kind of wanna get it there. And then again, there's kind of niche scenarios where you're really worried, maybe get a semen analysis and it doesn't look that good, arrange for the time of orchiectomy to have onco-testicular sperm extraction from the, quote unquote, "normal" testis parenchyma. You know, I think you have to be kind of prepared to go that route and really make sure you're doing this completely comprehensively.  So pre-orchiectomy all patients. Don't really push for it too hard if they've got a contralateral testicle, if they've had no issues having children. There's some cost associated with this, sperm banking still isn't kind of covered even in the context of men with cancer. If they've got risk factors, absolutely pre-orchiectomy. Pre-RPLND, even though the rates of ejaculatory dysfunction at a high-volume center should be low single digits, I'll still offer it. That'd be a real catastrophe if they were in that small proportion of patients and now they're going to be reliant on things like intrauterine insemination, where it becomes quite expensive.  Pre-chemo, everybody. That's basically a standard these days where it should be discussed and it's kind of amazing currently, even if you don't have an accessible men's health fertility clinic, there are actually companies, I have no vested interest, Fellow is one such company where you can actually create an account, receive a FedEx semen analysis and cryopreservation kit, send it back in, and all CLIA certified, it's based out of California. The gentleman that runs it, is a urologist and very, very bright guy who's done a lot of great stuff for testis cancer. So, even for patients that are kind of in extremis at the hospital that kind of need to get going like yesterday, we still discuss it. We've got some mechanisms in place to either have them take a semen analysis over to our Men's Health clinic or send it off to Fellow, which I think is pretty cool and that even extends to some of our younger adolescent patients where going to a clinic and providing a sample might be tricky.  So, I think bringing it up every stage, anytime there's an intervention that might be offered, orchiectomy, chemo, surgery, radiation, it's kind of incumbent on us to discuss it. Dr. Pedro Barata: Gotcha. That's super helpful. And you also touch base on another angle, which is the psychosocial angle around this. You mentioned suicidal rates, you mentioned anxiety, perhaps depression in some cases as well as chronic fatigue, not necessarily just because of the low testosterone that you can get, but also from a psychological perspective. I'm curious, what do the recommendations look like for that? Do these patients need to see a social worker or a psychologist, or do they need to answer a screening test every time they come to see us and then based on that, we kind of escalate, take the next steps according to that? Do they see a psychologist perhaps every so often? How should that be managed and addressed? Dr. Aditya Bagrodia: It's an excellent question and again, these can be rather insidious symptoms where if you don't really dig in and inquire, they can be glossed over. I mean, how easy to say, "Your markers look okay, your scans look okay. See you in six months," and keep it kind of brief. First off, I think bringing it up proactively and normalizing it, that, "This may be something that you experience. Many people do, you're not alone, there's nothing kind of wrong with you." I also think that this is an area where support groups can be incredibly useful. We host the Testicular Cancer Awareness Foundation support group here. They'll talk about chemo brain or just like a little bit of an adjustment disorder after their diagnosis. Support groups, I think are critical. As I mentioned, we have a survivorship program that's led by a combination of our med oncs, myself on the uro-onc side, as well as APPs, where we are systematically asking about essentially the whole litany of issues that may arise, including psychosocial, anxiety, depression, suicidality. And we've got a nice kind of fast path into our cancer center support services for these young men to meet with a psychologist. If that isn't going to be sufficient, they can actually see a psychiatrist to discuss medications and so forth. I do think that we've got to screen for these because, as anticipated from diagnosis, those first 2 years, we see a rise. But even 10, 15 years out, we note, compared to controls, that there is an increased level of anxiety, depression, suicidality that might not just take place at that initial acute period of diagnosis and treatment. Dr. Pedro Barata: Really well said. Super important.  So I guess if I were to put all these together, with these really amazing advances in technology, we all know AI, some of us might be more or less aware of biomarkers coming up, including microRNA for example, and others, like as I think of all these potential long term complications for these patients, look at the future, I guess, can we use this as a way to deescalate treatment where it's not really necessary, as a way to actually prevent some of these complications? Like, how do we see where we're heading? As we manage testicular cancer, let's say, within the next 5 or 10 years, do you think there's something coming up that's going to be different from what we're doing things today? Dr. Aditya Bagrodia: Totally. I mean, I think it's as exciting as a time as there's ever been, you know, maybe notwithstanding circa 1970s when platinum was discovered. So microRNAs, which you mentioned, you know, there's a new candidate biomarker, microRNA-371. We are super excited here at UCSD. We actually have it CLIA-certified available in our lab and are ordering these tests for patients kind of in their acute stage, you know, stage one and surveillance, stage two, post-RPLND, receiving chemotherapy. And essentially this is a universal germ cell tumor specific biomarker, except for teratoma, suffice it to say 90% sensitive and specific. And I think it's going to change the way that we diagnose and manage patients. You know, pre-orchiectomy, that's pretty straightforward. Post-orchiectomy, maybe we can really decrease the number of CT scans that are done. Maybe we can identify those patients that basically have occult disease where we can intervene early, either with RPLND or single cycle chemo. Post-RPLND, identify the patients who are at higher risk of relapse that may benefit from some adjuvant therapy. In the advanced setting, look at marker decline for patients in addition to standard tumor markers. Can we modulate their systemic therapy?  So, the international interest is largely on modifying things. There's really cool clinical trials that we have for stage one patients, that treatment would be prescribed based on a post-orchiectomy microRNA. I think the microRNAs are really exciting. Teratoma remains an outstanding question. I think this is where maybe ctDNA, perhaps some radiomics and advanced imaging processing and incorporating AI may allow us to safely avoid a lot of these post-chemo RPLNDs. And then identification using SNPs and so forth of who might be most susceptible to some of the cardiac toxicity, autotoxicity and personalizing things in that way as well. Dr. Pedro Barata: Super exciting, right, what's about to come? And I agree with you, I think it's going to change dramatically how we manage this disease.  This has been a pleasure sitting down with you. I guess before letting you go, anything else you'd like to add before we wrap it up? Dr. Aditya Bagrodia: Yeah, first off, again, just want to thank you and ASCO for the opportunity. And it's easy enough to, I think, approach a patient with the testicular germ cell tumor as, "This is an easy case. We're just going to do whatever we've done. Go to the guidelines that says do X, Y, or Z." But there's so much more nuance to it than that. Getting it done perfectly, I think, is mandatory. Whatever we do is an impact on them for the next 50, 60, 70 years of their life. And I found the germ cell tumor community, people are really passionate about it. If you're ever uncertain, there's experts throughout the country and internationally. Ask somebody before you do something that you can't undo. I think we owe it to them to get it perfect so that we can really maximize the survivorship and the survival like we've been talking about. Dr. Pedro Barata: Aditya, thanks for sharing your fantastic insights with us on this podcast. Dr. Aditya Bagrodia: All right, Pedro. Fantastic. Appreciate the opportunity. Dr. Pedro Barata: And also, thank you to our listeners for your time today. I actually encourage you to check out Dr. Bagrodia's article in the 2025 ASCO Educational Book. We'll post a link to the paper in the show notes. Remember, it's free access online, and you can actually download it as well as a PDF. You can also find on the website a wealth of other great papers from the ASCO Educational Book on key advances and novel approaches that are shaping modern oncology.  So with that, thank you everyone. Thank you, Aditya, one more time, for joining us. Thank you, have a good day. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:         Dr. Pedro Barata  @PBarataMD   Dr. Aditya Bagrodia @AdityaBagrodia Follow ASCO on social media:         @ASCO on X (formerly Twitter)         ASCO on Bluesky        ASCO on Facebook         ASCO on LinkedIn         Disclosures:      Dr. Pedro Barata:  Stock and Other Ownership Interests: Luminate Medical  Honoraria: UroToday  Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon  Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas  Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck   Dr. Aditya Bagrodia: Consulting or Advisory Role: Veracyte, Ferring  

QUOTES from the Episode "Instead of landlines everywhere, give every heat pump a cell phone and let it call home." "We're seeing close to 40% of heat pumps undercharged or leaking—no wonder callbacks are high." "What gets measured gets managed." — often attributed to Peter Drucker (fitting this data-driven shift)   Brendan Hermalyn (CEO/founder, Thalo Labs) traces a zig-zag path from NASA and defense to self-driving cars—then into HVAC. His through-line: high-reliability sensing and prognostics. Thalo's product aims to "give every heat pump a cell phone," using a small, non-invasive module that snaps inside VRFs/splits (and eventually larger plants), measures power and line temps, backhauls via cellular, and flags undercharge/leaks and power-quality issues before they become emergency calls. It's equipment management, not a full BMS—lightweight to install, built for techs, and friendly to API integrations, texts, and weekly roll-ups. Brendan argues the market is ready: most commercial buildings still lack BMS, Wi-Fi is fragile for critical telemetry, and the economics of sensors/cloud have flipped. Thalo avoids tapping the refrigerant loop, prioritizes fast installs (often 10–30 minutes), QR/location tagging, and even a "buzz this unit" feature to find the right rooftop box. Early field data is sobering—he's seeing ~40% of heat pumps undercharged and/or leaking—driving callbacks, compressor failures, and energy waste. The pitch to contractors: turn break-fix chaos into planned maintenance, white-label the savings report, and train new techs faster with data-driven cues. Oh, and the name? "Thalo" like the deep sky blue—an homage to adding tech to make the picture clearer.   Brendan's LinkedIn: https://www.linkedin.com/in/brendan-hermalyn/ Thalo Labs: https://thalolabs.com/   This episode was recorded in October 2025.  

Totex co-founder Berlin Raj joins Eric and “Overkill Bill” to unpack a single-box, hydronic monoblock system that combines space conditioning, domestic hot water, pool heating, thermal + lithium storage, EV charging integration, and backup power. Born from Berlin's lifelong tinkering (and many shocks), the idea: stop wasting condenser heat—capture it for hot water while cooling. The system keeps all refrigerant sealed in the outdoor unit and runs PEX supply/return to indoor air handlers (ducted or ductless), avoiding field flares and refrigerant line runs. Install looks familiar—set the pad, pipe PEX, fill a glycol loop, wire power/control—yet it adds clever tricks: load matching from ~1.5–6 tons, dynamic load limiting for small panels (even ~20–30A circuits), modular thermal storage (~100 kWh cooling / ~55 kWh heating), a ~10.5 kWh lithium pack, and app/10" touchscreen controls over Modbus with hooks for BMS and home automation. In cooling-plus-hot-water mode, field tests show very high effective COP (Berlin cites “9+”) because the unit harvests both sides of the cycle. Engineered for residential and light commercial (think houses, small offices, QSRs), the unit can supply hot water up to ~165°F, support radiant/underfloor at lower temps, operate down to about -7.6°F, and be manifolded for capacity and redundancy. Texas is the target U.S. beachhead (long cooling seasons = months of “free” hot water), with pilots in Australia and U.S. pilots planned; broader availability is aimed for mid to late next year. Berlin's closing note? “People, people, people”—comfort and outcomes start with humans. Notable Quotes: “Why dump condenser heat when you can use it? Cool the house and make hot water at the same time.” — Berlin Raj “Dynamic load balancing means a heat pump that plays nice with a 100-amp panel.” — Eric Kaiser (paraphrased) “People, people, people. Comfort is ultimately about humans first.” — Berlin Raj   Berlin on LinkedIn:https://www.linkedin.com/in/berlinrajm/ Totex website: https://www.totexenergy.com/ Come visit with Berin in person at the www.USHeatPumpSummit.com     This episode was recorded in September 2025.  

This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and strategic movements shaping the landscape of healthcare. Let's start with a recent spotlight on the European Society for Medical Oncology Congress 2025, where key clinical trial outcomes have emerged, potentially reshaping future treatment protocols.AstraZeneca made waves with its Phase 3 trial results for Imfinzi, a PD-L1 inhibitor, in high-risk non-muscle invasive bladder cancer. The findings suggest that Imfinzi stands strong against Pfizer's PD-1 candidate, Sasanlimab. This is particularly noteworthy as bladder cancer has historically had limited non-invasive treatment options. The implications for patient care are substantial, providing hope for improved management of this form of cancer and possibly influencing treatment standards.Meanwhile, Eli Lilly's Verzenio marked another success at the ESMO Congress with its overall survival win in early breast cancer cases. This victory enhances Verzenio's standing within the CDK4/6 inhibitor class, suggesting increased adoption in clinical settings. The demonstration of extended survival benefits not only strengthens Verzenio's competitive position but also contributes to setting a new standard of care in early breast cancer treatment.On the regulatory front, Sanofi encountered mixed outcomes from the European Medicines Agency's Committee for Medicinal Products for Human Use. While Rezurock was not recommended as a third-line treatment for chronic graft-versus-host disease, this decision underscores the stringent regulatory processes companies navigate despite existing market success in other regions like the U.S.In a significant move by the FDA to expedite drug approvals, nine companies including Merck KGaA and Regeneron received priority review vouchers. These vouchers allow a shortened review timeline, reflecting an ongoing trend towards accelerating drug availability to address unmet medical needs swiftly.In terms of strategic developments, EMD Serono—Merck KGaA's U.S. branch—has unveiled a major discount initiative for its IVF treatments on the TrumpRx platform. This aligns with broader efforts to make fertility treatments more accessible amidst rising demand and economic pressures.The metabolic dysfunction-associated steatohepatitis (MASH) arena is also witnessing robust interest with over $10 billion recently reported in mergers and acquisitions. This surge indicates confidence among Big Pharma players in MASH as a lucrative therapeutic field ripe for innovation and development.In response to competitive pressures and operational challenges, Kezar Life Sciences is preparing for layoffs following the FDA's decision to cancel a critical meeting related to its R&D program. This situation illustrates the volatile dynamics within biotech firms where regulatory decisions can significantly impact corporate strategies and workforce stability.Overall, these developments reflect an industry characterized by rapid innovation, strategic realignments, and an evolving regulatory framework. The implications for patient care are substantial as these scientific advancements promise enhanced treatment options across various therapeutic areas.Switching gears to scientific developments, Bristol Myers Squibb has reported promising results from early-stage trials of its EGFRxHER3 antibody-drug conjugate. Demonstrating a 55% overall response rate, this positions BMS to potentially gain a competitive edge in the ADC market—a sector valued for targeting cancer cells while minimizing side effects on healthy tissues.Strategic partnerships continue to shape industry growth and innovation. Roche has secured a deal with Hansoh Pharmaceutical worth up to $1.45 billion for global rights to an experimental ADC outside Greater China. SimilSupport the show

Adam Haman returns to first comment on the recent Nick Fuentes rehabilitation tour, and then the main event: Analyzing the Coleman Hughes vs. Dave Smith debate.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.Coleman Hughes vs. Dave Smith.Dave Smith responds to the "seven countries in five years" challenge.This episode's sponsor, The Swan Brothers.BMS ep 95 with Tareq Haddad on the OPCW Syria scandal.The HamanNature substack.Help support the Bob Murphy Show.

Hello to our lovely coven, happy Wednesday! Katie and Dayna are joined by the coven's favorite boyfriend, Nick Martin! The chaos is immediate, starting with BMs, lice, and the truly cursed Poop Tic Tac. Nick shares about  life as a touring musician turned domestic boyfriend, Katie flexes her perfume powers, Dayna explains her anti-Labubu agenda, and the group dives into HomeGoods shame, celebrity sightings, and embarrassing things that shouldn't be embarrassing. In need of something cute and cool for the summer? Get yourself or whoever's on your daddy list a tee, hoodie, or daddy hat from our store! Please support our show and show off your love for Disrespectfully by repping our official gear :) K Love ya bye! Thank you to our sponsors! Betterhelp: This episode is brought to you by BetterHelp. Give online therapy a try at https://betterhelp.com/disrespectfully and get on your way to being your best self Hero Bread: Hero Bread is offering 10% off your order. Go to https://hero.co and use code DISRESPECTFULLY10 at checkout ZipRecruiter: Try ZipRecruiter FOR FREE at https://ZipRecruiter.com/DISRESPECT Quince: Go to https://Quince.com/disrespectfully for free shipping on your order and 365-day returns Willie's Remedy: Order now at https://drinkwillies.com and use code DISRESPECTFULLY for 20% off of your first order + free shipping on orders over $95, and enjoy life in the high country Connect with the Coven! Facebook: https://www.facebook.com/groups/1930451457469874 Reddit: https://www.reddit.com/r/disrespectfullypod/ Listen to us on Apple: https://podcasts.apple.com/us/podcast/disrespectfully/id1516710301 Listen to us on Spotify: https://open.spotify.com/show/0J6DW1KeDX6SpoVEuQpl7z?si=c35995a56b8d4038             Follow us on Social! Disrespectfully Instagram: https://www.instagram.com/disrespectfullypod Disrespectfully Tiktok: https://www.tiktok.com/@disrespectfullypod Katie Maloney Instagram: https://www.instagram.com/musickillskate Nick Martin Instagram: https://www.instagram.com/nodirectioncasa Dayna Kathan Instagram: https://www.instagram.com/daynakathan Leah Glouberman Instagram: https://www.instagram.com/leahgsilberstein Allison Klemes Instagram: https://www.instagram.com/allisonklemes/ Buy our merch! https://disrespectfullypod.com/ Disrespectfully is an Envy Media Production.

In this episode of the RCP Medicine Podcast, Consultant Respiratory Physician Milind Savani joins Respiratory Registrar Daniella Draicchio and Foundation Doctor Masooma Ali to explore a compelling case of progressive breathlessness in a 45-year-old woman. What begins as a seemingly routine presentation unfolds into a diagnostic journey.Together, the team discusses the challenges of diagnosing chronic type 2 respiratory failure, the importance of recognising paradoxical breathing, and the role of non-invasive ventilation and surgical intervention. This episode is a masterclass in clinical reasoning, multidisciplinary collaboration, and the value of thorough bedside examination.ReferencesA retrospective cohort study of idiopathic diaphragmatic palsy: a diagnostic triad, natural history and prognosis ERJ Open Research 2021 00953-2020; DOI: https://doi.org/10.1183/23120541.00953-2020 Diagnosis and management of nontraumatic unilateral diaphragmatic paralysis (complete or partial) in adults - UpToDateTreatment of diaphragmatic paralysis using an expanded surgical protocol: review of the largest worldwide experience  European Respiratory Journal 2018 52 (suppl 62): PA806; DOI: https://doi.org/10.1183/13993003.congress-2018.PA806 Diaphragm dysfunction: how to diagnose and how to treat? Breathe 2025 21(1): 240218; DOI: https://doi.org/10.1183/20734735.0218-2024 This podcast has been made with an educational grant from Bristol-Myers Squibb Pharmaceuticals Limited (“BMS”). BMS has had no input or involvement in the design, development or content of the podcast whatsoever.RCP Links Education Events Membership Improving care Policy and campaigns RCP Social Media Instagram LinkedIn Facebook X Bluesky Music: Episode 50 onward - Bensound.com Episodes 1 - 49 'Impressive Deals' - Nicolai Heidlas

Audio roundup of selected biopharma industry content from Scrip over the business week ended September 26, 2025. In this episode: Pfizer jumps back into obesity with Metsera bid; Roche maps out its obesity ambitions; UniQure's encouraging gene therapy results for Huntington's; BMS plans US pricing for Cobenfy in the UK; and vaccine skepticism affects vaccine commercial prospects. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-HCVAK32IGREDHMH5D4I3RFY6AA/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Dan: my daughter 11 years old now has had for some time very large dense and hard bowel movements. our family doctor had her taking miralax at smaller doses but no solutions for long term. we have tried making sure she gets enough fiber and water but do not know what is causing this or where to start. i literally have to break up her BMs to flush the toilet . thanks for your help                                                                                                                                                                            Charlene: hello and thank you for all your help. my wife and i have been on a body transformation journey for about two years now. we have not reached our goals, our goal is overall health but are trying to build muscle and eventually lower our body fat percentages to a healthy number. we have been on a high protein diet about a gram per pound of body weight . i know this is not great for long term. how long is too long to be on this sort of diet and how should we best go about cycling our diet for best results. trying to get down to the 20 - 30 % body fat from 40 -50%. we also strength train regularly                                                                                                                                                                                               Dan: my teenage son has alot of acne. nothing seems to do any good for it and its much worse under his shirt sleeves. our doctor wanted him to take an antibiotic di something or other. we have tried a couple or topical treatments but nothing seems to work how do we get to the bottom of this?                                          Jean: I wake up too many days now with brain fog, extreme fatigue, no energy and headaches. Different parts of my body have discomfort. Thank you for answering my question.                                                                                                                          Sheena: Hi Dr. C! Hope you and your team are well. (This is the third time I've written in regarding this question). My liquid vitamin D says 1 drop equals 1000iu. . I was wondering if I can trust that? Because it seems soo little compared to a tablet. I end up consuming more drops then I need to, just in case. Thx in advance for answering!               Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3523 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

What happens when cities become “networked”—and water systems start telling us what they need in real time? In this episode, Trace Blackmore speaks with Christine McHugh (CEO, White Strand Development) about practical smart-city strategies for water: real-time monitoring, digital twins, and IoT/AI approaches that turn Legionella control from periodic testing into continuous risk management. Christine frames smart water not as gadgets, but as a disciplined, data-driven process that improves human health, operational efficiency, and insurability. Building the “Networked” City: A Practical Definition   Christine defines a smart city as a networked one—linking health, energy, waste, and water through technology that measures and correlates across systems. The aim isn't novelty; it's safer drinking water and safer water environments via better data and faster decisions. Digital twins, decentralized treatment, and AI-enabled pattern recognition help teams move from “single point-in-time readings” to persistent trends they can act on. Legionella Risk, Reframed as Strategy   Most water programs still sample periodically, waiting days for results. Christine argues the future is pattern-based, proactive control: track temperature, stagnation/flow, and disinfectant continuously; intervene when pattern thresholds indicate elevated risk. This lens aligns water quality, human wellness, and insurance risk reduction, encouraging property insurers and building owners to incentivize water science as part of smart-building operations.  From Sensors to Sense-Making: Hierarchy, Data Lakes, and Reporting  Adding devices isn't enough. Christine stresses a hierarchy of sensors and data governance so operations, engineering, and ESG teams aren't running conflicting reports from siloed sources (BMS vs. cloud dashboards). Her model: create a data lake with agreed-upon sources of truth and standardized outputs so every stakeholder “sees the same movie.”  Case Studies & What “Good” Looks Like  Christine highlights programs that combined water management plans, continuous disinfectant monitoring, and campus-scale digital twins—reducing manual tests, achieving compliance, and cutting consumption. European hospitals using IoT on hot-water systems report faster compliance and fewer manual interventions. The pattern: real-time insight + trained people + maintenance and reporting contracts = measurable risk reduction.  Cybersecurity: Close the Back Doors  Smart water raises legitimate cyber concerns. Christine's guidance: encrypt all sensor communications, hire experts to penetration-test your own systems, and watch for unexpected bridges (e.g., HVAC or even “non-critical” devices) into critical networks. OT/IT segmentation, alert transparency, and a culture of continuous testing matter as much as the sensors themselves.  Public–Private Partnerships (with Academia)  The fastest path to adoption pairs public oversight and access to infrastructure with private-sector technology and capital—and an academic partner for research and validation. Clear performance metrics and maintained as-builts keep pilots honest and scalable.  Resilience: Droughts, Floods, and Stormwater  Smart networks matter beyond Legionella. Real-time consumption, leak detection, and pressure management minimize waste during droughts; stormwater and wastewater sensors prevent overflows that contaminate receiving waters during floods. Long-running sensor programs abroad show how a single resort area eliminated contamination events by instrumenting the system and responding to alerts.  Emerging Tech to Watch  From self-healing pipes and biosensors to drone inspections and AI-orchestrated networks, Christine sees water systems becoming more like natural ecosystems—self-regulating, adaptive, and resilient—while humans supervise exceptions and validate performance.  For industrial water professionals, the takeaway is clear: treat smart water as an integrated risk-management system, not a pile of devices. Invest in sensor hierarchy, unified data, and team training, and align the work with safety and insurance outcomes. That's how you protect people, performance, and the balance sheet. Stay engaged, keep learning, and continue scaling up your knowledge!    Timestamps  02:37 - Trace Blackmore kicks off the episode by reminiscing about the TV show Leave It to Beaver and how families used to watch together in the 1950s.  08:40 - Water You Know with James McDonald  09:48 - Upcoming Events for Water Treatment Professionals   12:20 - Interview with Christine McHugh, CEO of White Strand Development  13:03 -  What Is a Smart City?   15:13 - Risk Reduction as Strategy   16:23 – Real-Time Monitoring: Core Controls  17:06 - Smart Fixtures & “Only When Needed” Flushing  19:28 — Duplication, BMS vs Cloud, Data Governance  25:03 — Case Studies: VT & Copenhagen University Hospital  31:59— Cybersecurity: Water Systems at Risk  40:21— City Resilience: Drought & Flooding  41:59 — Emerging Tech to Watch    Quotes  “Technology will give us real-time patterns, and… by just having that pattern recognition, we have power to be more proactive.”   “We really should be trying to break into our own system or hiring people to break into our own system… the bad guys will find it as well.”   “Creating a water system that's more like a natural ecosystem… self-regulating, adaptive, and maximizes both efficiency and resiliency.”    Connect with Christine McHugh Phone: 9179409383  Email: christine.mchugh@whitestrand.com  Website: White Strand Development  LinkedIn: https://www.linkedin.com/in/christine-a-mchugh/     Guest Resources Mentioned   Practitioners' Perspective on the Prevalent Water Quality Management Practices for Legionella Control in Large Buildings in the United States  Tenets of a holistic approach to drinking water-associated pathogen research, management, and communication   Smart Cities, Copenhagen and the Power of Data   Chlorine Disinfection of Legionella spp., L. pneumophila, and Acanthamoeba under Warm Water Premise Plumbing Conditions  NLM's Water heater temperature set point and water use patterns influence Legionella pneumophila and associated microorganisms at the tap    Scaling UP! H2O Resources Mentioned  AWT (Association of Water Technologies)  Scaling UP! H2O Academy video courses  Submit a Show Idea  The Rising Tide Mastermind  Industrial Water Week     Water You Know with James McDonald  Question: What type of resin is primarily used in a sodium zeolite water softener?    2025 Events for Water Professionals  Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.   

 Adam creates a hypnosis session for a client with a form of phantom pain, that had no medical or neurological cause. Adam employs a metaphorical version of the scrambler technique to help reset and recalibrate the nerves that cause the false pain signals.

Spike Cohen returns to the podcast to elaborate on the tremendous success of his organization, You Are the Power. By simply spotlighting particular government officials abusing their position, his network can give people an incentive to do the right thing.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.This episode's sponsor, ExPatMoneySummit.com.The You Are the Power main page.BMS ep 369 featuring Spike Cohen on his adventures.Help support the Bob Murphy Show.

Bone marrow stimulation (BMS) is the most frequently performed surgical procedure for osteochondral lesions of the talus (OLTs). After the surgical intervention, one of the first goals of rehabilitation is to resume weightbearing. This study aims to compare clinical and radiologic outcomes between immediate weightbearing and delayed weightbearing, which represent unrestricted weightbearing and weightbearing starting at 6 weeks postoperatively. In conclusion, this matched cohort study found no statistically significant difference in clinical or radiologic outcomes at 12 months between immediate and delayed weightbearing following arthroscopic BMS for talar osteochondral lesions. Although early weightbearing may be feasible and well tolerated, the small sample size and wide CIs limit the strength of conclusions. These findings should be considered hypothesis-generating and underscore the need for larger, prospective trials. Click here to read the article

Jake Boldig was the one to introduce Bob to two previous BMS guests (Jonathan Menn and Protais Nshogoza). They all work for ECLEA--Equipping Church Leaders in East Africa. Jake tells Bob of his recent adventures in the Congo.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.This episode's sponsor, ExPatMoneySummit.com.The homepage of ECLEA.BMS ep 392 with Jonathan Menn (founder of ECLEA), and BMS ep 411 with Dr. Protais Nshogoza (survivor of Rwandan genocide).Help support the Bob Murphy Show.

Vaughn Halliday, MSc, CFM, SFP, FMP, PMP, ProFM is Manager of Support Services and Facilities for the Central Bank of Trinidad & Tobago where he is a seasoned management executive with a specialized focus on facilities and project management, underpinned by a fervent commitment to sustainability. Mike Petrusky asks Vaughn why he believes that FM professionals need to lead with purpose, adapt with precision, and invest in people as much as they do in technology. They discuss the constant tension between short-term operational demands and long-term asset stewardship which often leads to deferred maintenance and reactive decision-making and Vaughn shares how the effective use of data from CMMS and BMS platforms is essential for driving strategic outcomes. He says that facility managers should move beyond a maintenance mindset and embrace FM as a strategic enabler of business outcomes by investing in training and credential programs at events like IFMA's World Workplace. The future of FM is already here, with AI, IoT, and smart systems reshaping how assets are managed, so Mike and Vaughn encourage and inspire you to be an Asset Champion in your organization! Connect with Vaughn on LinkedIn: https://www.linkedin.com/in/vaughn-halliday/ Learn more about IFMA: https://www.ifma.org/ Explore Eptura™: https://eptura.com/ Discover free resources and explore past interviews at: https://eptura.com/discover-more/podcasts/asset-champion/ Connect with Mike on LinkedIn: https://www.linkedin.com/in/mikepetrusky/  

 Adam creates a hypnosis session to help a client release suppressed emotions that were linked to their burning mouth syndrome - BMS. This is designed to release emotions linked to words that were never said and so those emotions are suppressed - which means they can be released in this session.

Mathematician Ian Deters returns to the podcast to summarize the results of his computer simulations of a simple model of "free banking," as guided by Bob's instructions. His report has some good news and bad news for Bob.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.This episode's sponsor, ExPatMoneySummit.com.The website of Ian Deters, including contact info. Ian Deters' appearance on the BMS ep. 287 defending the use of infinite sets in higher mathematics.Bob's recent Human Action podcast episode explaining the Rothbardian view of free banking (and the in-built limits to credit expansion).The Selgin-White 1994 JEL article laying out their model of free banking.Bob's QJAE article critical of the Selgin-White approach to free banking.Help support the Bob Murphy Show.

Martha Bueno is a popular advocate for liberty whose parents fled communist Cuba. She is part of Lyn Ulbricht's new organization dedicated to freeing nonviolent offenders suffering from cruel sentencing.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.This episode's sponsor, PersistSEO.com.The homepage for MACS (Mothers Against Cruel Sentencing).Martha Bueno's X profile; the profile for MACS.Lyn Ulbricht's interview on the BMS.Help support the Bob Murphy Show.

 Adam creates a hypnosis session using the rewind technique and staged dissociation to help a client reduce symptoms to burning mouth syndrome (BMS), which the client felt was linked to a reaction of hearing the results of a scan, which turned out to be incorrect. Adam helps them connect the emotions to the same event if things had happened in a different order, breaking the connection with the original point of inception. 

Adam returns for another crossover, this time to discuss Peter Thiel's fascinating conversation with Ross Douthat.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.This episode's sponsor, The Swan Brothers.The Thiel/Douthat interview.BMS ep 421, building a billionaire's bunker.Bob's article explaining the distinction between Hayek's knowledge problem and Mises' calculation problem (of socialism).The HamanNature substack.Help support the Bob Murphy Show.

In a market flooded with cheap imports and geopolitical risk, one company is standing its ground.Did you know there's only one North American battery management system (BMS) provider at utility scale—despite growing pressure from subsidized Chinese competitors offering systems at zero cost? Michael Worry, CEO of Nuvation Energy, joins Nico to share how his company became that lone provider. But the core of this episode brings a critical warning: what happens when over 80% of the U.S. battery infrastructure is owned or influenced by foreign governments? And how should engineers and lawmakers respond?Michael takes us on a wild entrepreneurial ride: from building EVs before Tesla was cool to deploying robot kegerators at Burning Man. Nuvation's “garage projects” aren't just PR stunts—they're real-world user acceptance test platforms that prove product reliability under extreme conditions.Expect to learn:

Adam Haman and Bob Murphy interview Jacob Hornberger to get to the bottom of their differing views on libertarianism and immigration.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.BMS ep 416, which was a response to Hornberger's original critique of Adam and Bob. Jacob's response to them.The HamanNature substack.Help support the Bob Murphy Show.

Adam Haman returns to help Bob respond to a common string of objections he recently received, as feedback on a lecture given to the Menger Institute.Mentioned in the Episode and Other Links of Interest:The YouTube version of this conversation.Bob's lecture to the Menger Institute on private law (and defense).Bob's articles on warlords and the mafia.BMS ep 166 on Arrow's Theorem. Adam and Tyrone discuss Arrow.The HamanNature substack.Help support the Bob Murphy Show.